



PCT/GB 00/03525

REC'D	OCT 2000
WIPO	PCT



INVESTOR IN PEOPLE

GB00/3525

10 000187

4


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed 

Dated 18 September 2000

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)





The
**Patent
Office**

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference SMK/LP5795968

2. Patent applicant
(The Patent Office)

9922071.7

17 SEP 1999

3. Full name, address and postcode of the or of each applicant (underline all surnames)

PLANT BIOSCIENCE LIMITED
NORWICH RESEARCH PARK
COLNEY LANE
NORWICH
NORFOLK
NR4 7UH

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

1484982001

4. Title of the invention

METHODS AND MEANS FOR MODIFICATION OF PLANT CHARACTERISTICS

5. Name of your agent (if you have one)

MEWBURN ELLIS

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

YORK HOUSE
23 KINGSWAY
LONDON
WC2B 6HP

Patents ADP number (if you know it)

109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for each of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 56

Claim(s) 0

Abstract 0

Drawing(s) 9 + 9

10. If you are also filing any of the following, state how many against each item

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents 0
(Please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

16 September 1999

12. Name and daytime telephone number of person to contact in the United Kingdom SIMON M. KREMER 020 7240 4405

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

METHODS AND MEANS FOR MODIFICATION
OF PLANT CHARACTERISTICS

TECHNICAL FIELD

5

The present invention relates generally to methods and materials for use in modifying plant characteristics, particularly the vernalization response in plants.

10

PRIOR ART

Plants must integrate a wide variety of environmental signals in order to maximize their reproductive success. Part of this integration must involve perception of the seasons, both to ensure the plant flowers during the correct season (for which it is adapted) and to synchronise its flowering with other members of its own species, to increase the chances of cross-fertilization. *Arabidopsis thaliana* serves as a model plant, for it exhibits responses to a wide variety of environmental stimuli that are observed in many species. Amongst other stimuli, flowering in naturally occurring strains (ecotypes) of *Arabidopsis* can be promoted by vernalization, a long cold treatment that mimics the cold of winter.

20

25

Many species of plants that grow in temperate or cooler climes have an obligate requirement for vernalization in order to flower. Such plants typically germinate in autumn, and over winter as vegetative plants, and flower in milder conditions of spring. Vernalization thus acts as a cue, to allow plants to sense the seasons, and to time their flowering to maximise their chance of reproductive success.

30

35

Species for which flowering is important to crop production are numerous, essentially all crops which are grown from seed, with important examples being the cereals, rice and maize, probably the most agronomically important in warmer climatic zones, and wheat, barley, oats and rye in more temperate climates.

40

Important seed products are oil seed rape, sugar beet, maize, sunflower, soybean and sorghum. Many crops which are harvested for their roots are, of course, grown annually from seed and the production of seed of any kind is very dependent upon the ability of the plant to flower, to be pollinated and to set

seed. In horticulture, control of the timing of flowering is important. Horticultural plants whose flowering may be controlled include lettuce, endive and vegetable brassicas including cabbage, broccoli and cauliflower, and carnations and geraniums.

In view of the large number of commercially important crop species which have a requirement for vernalization in order to flower, modification of this requirement (e.g. by reducing the duration of vernalization required, or changing the optimum temperature, or abrogating the requirement altogether) would be of agronomic interest.

DISCLOSURE OF THE INVENTION

The inventors have used a late flowering, vernalization responsive mutant of *Arabidopsis*, the *fca* mutant, as a background in which to isolate mutants that exhibit a reduced vernalization response and to identify *vrn1* alleles which are responsible for this phenotype. The *VRN1* gene is the first *Arabidopsis* flowering time gene to be isolated that is apparently exclusive to the vernalization promotion pathway. As discussed in more detail below, manipulation of the gene may permit the control or modification of the vernalization response of agronomically important crop species.

That *VRN1* is required for a normal vernalization response is clear from the phenotype of the *vrn1* mutants. Further experiments by the inventors indicate that there is a quantitative aspect to *VRN1* activity. This suggests that artificially increasing or decreasing the amount of *VRN1* (e.g., through overexpression or antisense suppression) may provide a tool to, *inter alia* fine-tune the kinetics and/or optimal temperature of the vernalization response; render plants immune to the effect of cold on flowering response; or alleviate the requirement for cold treatment altogether. In addition to quantitative manipulation, a further layer of control could be obtained by driving *VRN1* sense or anti-sense constructs using promoters that are either on all the time (constitutive); inducible upon application of a specific molecule; or which "naturally" drive expression only during a certain portion of the plant life cycle, e.g., seed maturation or late vegetative

phase.

Such methods could be used to improve agronomically important crop species, for instance as follows:

(a) Extension of geographic range of elite varieties: If an elite cultivar of a crop originates from a geographic area where it has adapted to require a certain vernalization period, and it is therefore climatically-limited in its range, then fine-tuning the expression of *VRN1* may permit alteration of the length and intensity of cold treatment required to achieve an optimum flowering time in new geographic areas. Two facts are noteworthy in this regard: (1) even modest alterations in vernalization response could open up huge new areas of cultivation for particular elite varieties (an analogous situation to that in which small changes in climatic conditions can alter the ecology and character of huge areas of landscape), and (2) the commercial success of elite genotypes is largely hampered by dependency on specific climatic conditions found in limited geographic areas.

(b) Shortening of vernalization period: if a winter crop can be sown and left in the ground for a shorter period than usual (i.e. a reduced vernalization time, perhaps resulting from increased- or mis-expression of *VRN1*) this may reduce the risk associated with severe winter weather conditions, as the crops are exposed to winter conditions for a shorter time.

(c) Extension of vegetative growth: If the crop in question is one in which the vegetative portions of the plant are the desired product (e.g., leaf vegetables, sugar beet), then preventing the plant from flowering in response to cold temperature (i.e., by rendering it less sensitive to the cold by impairing *VRN1* function) would prevent diversion of valuable plant resources from the vegetative tissues to the developing reproductive tissues, thereby increasing yield.

Further experiments indicate that species other than *Arabidopsis* contain genes similar to *VRN1*. Additionally, homologues and/or orthologues and/or paralogues of *VRN1* (such as *RTV1*) may also exist in *Arabidopsis* and other species. Based on the disclosure herein, such genes may be isolated

without undue burden by those skilled in the art and used analogously to those disclosed herein.

These and other aspects of the present invention will now be discussed in more detail.

Thus according to one aspect of the present invention there is provided an isolated nucleic acid molecule which is capable of specifically altering the vernalisation response of a plant into which the nucleic acid is introduced.

The alteration in the vernalisation response may be assessed by comparison with a plant in which the nucleic acid has not been so introduced.

The vernalization response phenotype of plants may be investigated by examining their flowering time in response to differing durations of vernalization treatment. In the experiments below this was assessed in two ways: (1) as the total number of vegetative leaves produced prior to flowering (LN), and (2) as the time in days from the end of the vernalization treatment to the appearance of the first floral bud (FT). However any appropriate method known to those skilled in the art may be used.

Apart from the specific change in vernalisation response, it is preferred that other characteristics of the plant are substantially unchanged by the polypeptide, which is to say that the polypeptide acts specifically on this response and not more generally on flowering time characteristics or other stimuli, such as those mediated by other loci such as the *FRI* locus (Clarke and Dean, 1994, Mol. Gen. Genet. 242, 81-89) or the *VRN2* locus (Chandler et al., 1996).

Preferably the isolated nucleic acid molecule capable of specifically altering the vernalisation response of a plant is obtainable from the *VRN1* locus of a plant, more preferably from *A. thaliana*.

Nucleic acid according to the present invention may include cDNA, RNA, genomic DNA and modified nucleic acids or nucleic acid analogs (e.g. peptide nucleic acid). Where a DNA sequence

is specified, e.g. with reference to a figure, unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed. Nucleic acid molecules according to the present invention may be provided isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or free or substantially free of other nucleic acids of the species of origin. Where used herein, the term "isolated" encompasses all of these possibilities. The nucleic acid molecules may be wholly or partially synthetic. In particular they may be recombinant in that nucleic acid sequences which are not found together in nature (do not run contiguously) have been ligated or otherwise combined artificially. Alternatively they may have been synthesised directly e.g. using an automated synthesiser.

Thus in one aspect of the invention, there is disclosed a nucleic acid encoding the polypeptide of Fig 7. The VRN1 polypeptide is 341 amino acids in length and is comprised of at least three regions. Region 1 (residues 2-94 in Figure 7) and 3 (residues 239-332) can be aligned to each other, and are related to the B3 DNA-binding domain originally found in the maize transcription factor VIVIPAROUS1 (VP1; McCarty et al., 1991). Region 2 of VRN1 (residues 95-238), which lies between the two B3 domains is not obviously related to any domain of known function, nor does it have obvious features of a transcriptional activation or repression domain. Nonetheless, region 2 does contain several provocative sequence features and motifs, including a putative nuclear localization signal (NSL), two putative PEST regions, and three RXXL motifs also associated with rapid protein degradation (Cooper et al., 1997). Interestingly, the second PEST region of VRN1 contains a potential protein kinase C (PKC) phosphorylation site (residues 176-178).

One nucleic acid encoding this polypeptide is shown in Fig 7 from nucleotides 269-1295 inclusive (including stop codon). Other nucleic acids of the invention include those which are degeneratively equivalent to this.

A genomic sequence including the VRN1 locus is shown in Annex I. The putative cDNA sequence transcribed from this genomic

sequence is shown at Fig 7. Although this ORF has been designated the VRN1 ORF herein, it will be appreciated by those skilled in the art that the discussion hereinafter applies equally to any other ORF present in the described sequence which has the properties attributed to VRN1.

In a further aspect of the present invention there are disclosed nucleic acids which are variants of the VRN1 sequences discussed above.

A variant nucleic acid molecule shares homology with, or is identical to, all or part of the sequences discussed above.

Such variants may be used to alter the vernalisation characteristics of a plant, as assessed by the methods disclosed herein. For instance a variant nucleic acids may include a sequence encoding a functional polypeptide (e.g. which may be a variant of the VRN1 polypeptide and which may cross-react with an antibody raised to said polypeptide). Alternatively they may include a sequence which interferes with the expression or activity of such a polypeptide (e.g. sense or anti-sense suppression of a VRN1 coding sequence).

Variants may also be used to isolate or amplify nucleic acids which have these properties (e.g. by inclusion of a sequence which is hybridisable with a VRN1 sequence.).

Generally speaking variants may be:

(i) Novel, naturally occurring, nucleic acids, isolatable using the sequences of the present invention. They may include alleles (which will include polymorphisms or mutations at one or more bases - for instance *vrn1-1* or *vrn1-2* shown in Fig 7) or pseudoalleles (which may occur at closely linked loci to the VRN1 gene). Also included are paralogues, isogenes, or other homologous genes belonging to the same family as the VRN1 gene. Although these may occur at different genomic loci to the gene, they are likely to share conserved regions with it (see e.g. RTV1 in the Examples below). Also included are homologues of VRN1 from other plant species.

(ii) Artificial nucleic acids, which can be prepared by the

skilled person in the light of the present disclosure. Such derivatives may be prepared, for instance, by site directed or random mutagenesis, or by direct synthesis. Preferably the variant nucleic acid is generated either directly or indirectly (e.g. via one or more amplification or replication steps) from an original nucleic acid having all or part of the VRN1 sequence shown in Fig 7.

Particularly included are variants which comprise only a distinctive part or fragment (however produced) corresponding to a portion of the sequence provided. The fragments may encode particular functional parts of the polypeptide. Alternatively, the fragments may have utility in probing for, or amplifying, the sequence provided or closely related ones. Suitable lengths of fragment, and conditions, for such processes are discussed in more detail below.

Also included are nucleic acids corresponding to those above, but which have been extended at the 3' or 5' terminus.

The term 'variant' nucleic acid as used herein encompasses all of these possibilities. When used in the context of polypeptides or proteins it indicates the encoded expression product of the variant nucleic acid.

Some of the aspects of the present invention relating to variants will now be discussed in more detail.

Homology (similarity or identity) may be assessed as set out in the Materials and Methods section in the Examples below.

Homology may be at the nucleotide sequence and/or encoded amino acid sequence level. Preferably, the nucleic acid and/or amino acid sequence shares at least about 65%, or 70%, or 80% identity, most preferably at least about 90%, 95%, 96%, 97%, 98% or 99% identity.

Homology may be over the full-length of the relevant sequence shown herein, or may be over a part of it, preferably over a contiguous sequence of about or greater than about 20, 25, 30, 33, 40, 50, 67, 133, 167, 200, 233, 267, 300, or more amino acids or codons, compared with Fig 7.

Thus a variant polypeptide encoded by a nucleic acid of the present invention may include within the sequence shown in Fig 7, a single amino acid or 2, 3, 4, 5, 6, 7, 8, or 9 changes, about 10, 15, 20, 30, 40 or 50 changes, or greater than about 50, 60, 70, 80 or 90 changes.

In a further aspect of the invention there is disclosed a method of producing a derivative nucleic acid comprising the step of modifying any of the sequences disclosed above, particularly the coding sequence of Fig 7.

Changes may be desirable for a number of reasons. For instance they may introduce or remove restriction endonuclease sites or alter codon usage.

Alternatively changes to a sequence may produce a derivative by way of one or more of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid, leading to the addition, insertion, deletion or substitution of one or more amino acids in the encoded polypeptide.

Such changes may modify sites which are required for post translation modification such as cleavage sites in the encoded polypeptide; motifs in the encoded polypeptide for phosphorylation etc. (e.g. residues 176-178 in Figure 7). Leader or other targeting sequences (e.g. membrane or golgi locating sequences) may be added to the expressed protein to determine its location following expression if it is desired to isolate it from a microbial system.

Other desirable mutations may be random or site directed mutagenesis in order to alter the activity (e.g. specificity) or stability of the encoded polypeptide. Changes may be by way of conservative variation, i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. As is well known to those skilled in the art, altering the primary structure of a polypeptide by a conservative substitution may not significantly alter the activity of that peptide because the side-chain of the amino

acid which is inserted into the sequence may be able to form similar bonds and contacts as the side chain of the amino acid which has been substituted out. This is so even when the substitution is in a region which is critical in determining the peptides conformation. Also included are variants having non-conservative substitutions. As is well known to those skilled in the art, substitutions to regions of a peptide which are not critical in determining its conformation may not greatly affect its activity because they do not greatly alter the peptide's three dimensional structure. In regions which are critical in determining the peptides conformation or activity such changes may confer advantageous properties on the polypeptide. Indeed, changes such as those described above may confer slightly advantageous properties on the peptide e.g. altered stability or specificity.

Particular regions, or domains, of VRN1 may have utility in their own right. For instance the B3 domains may be used to direct gene expression in a precise manner, for instance by the recognition of specific DNA sequences that represent elements in the promoters of their normal target genes. By creating fusion proteins, comprising the DNA binding domain (or domains) of VRN1, and a heterologous activation or repression domain borrowed from another protein, the expression of VRN1 target genes could be controlled. This may lead to a precise control of the expression of those genes that are normally targets of VRN1. Given that such genes, alone or in combination, ultimately control the transition to flowering (usually following vernalization), their directed expression in other conditions may provide a useful means to control flowering. Furthermore, the use of fusions based on the DNA binding domains in conventional SELEX or one-hybrid experiments may be used to reveal the target genes or DNA sequences normally bound by VRN1. Thus nucleic acids encoding these domains, or fusion proteins comprising them, form one embodiment of this aspect of the present invention.

In a further aspect of the present invention there is provided a method of identifying and/or cloning a VRN1 nucleic acid variant from a plant which method employs a sequence described above.

In one embodiment, nucleotide sequence information provided

herein may be used in a data-base (e.g. of ESTs, or STSs) search to find homologous sequences, such as those which may become available in due course, and expression products of which can be tested for activity as described below.

5 In another embodiment the nucleotide sequence information provided herein may be used to design probes and primers for probing or amplification. An oligonucleotide for use in
10 probing or PCR may be about 30 or fewer nucleotides in length (e.g. 18, 21 or 24). Generally specific primers are upwards of 14 nucleotides in length. For optimum specificity and cost effectiveness, primers of 16-24 nucleotides in length may be preferred. Those skilled in the art are well versed in the design of primers for use in processes such as PCR. If
15 required, probing can be done with entire restriction fragments of the gene disclosed herein which may be 100's or even 1000's of nucleotides in length. Small variations may be introduced into the sequence to produce 'consensus' or 'degenerate' primers if required.

20 Such probes and primers form one aspect of the present invention.

25 Probing may employ the standard Southern blotting technique. For instance DNA may be extracted from cells and digested with different restriction enzymes. Restriction fragments may then be separated by electrophoresis on an agarose gel, before denaturation and transfer to a nitrocellulose filter. Labelled probe may be hybridised to the single stranded DNA fragments on
30 the filter and binding determined. DNA for probing may be prepared from RNA preparations from cells. Probing may optionally be done by means of so-called 'nucleic acid chips' (see Marshall & Hodgson (1998) Nature Biotechnology 16: 27-31, for a review).

35 In one embodiment, a variant in accordance with the present invention is obtainable by means of a method which includes:

- 40 (a) providing a preparation of nucleic acid, e.g. from plant cells. Test nucleic acid may be provided from a cell as genomic DNA, cDNA or RNA, or a mixture of any of these, preferably as a library in a suitable vector. If genomic DNA is used the probe may be used to identify untranscribed regions of the gene (e.g. promoters etc.), such as are described hereinafter,
45 (b) providing a nucleic acid molecule which is a probe or

primer as discussed above,

(c) contacting nucleic acid in said preparation with said nucleic acid molecule under conditions for hybridisation of said nucleic acid molecule to any said gene or homologue in said preparation, and,

(d) identifying said gene or homologue if present by its hybridisation with said nucleic acid molecule. Binding of a probe to target nucleic acid (e.g. DNA) may be measured using any of a variety of techniques at the disposal of those skilled in the art. For instance, probes may be radioactively, fluorescently or enzymatically labelled. Other methods not employing labelling of probe include amplification using PCR (see below), RN'ase cleavage and allele specific oligonucleotide probing. The identification of successful hybridisation is followed by isolation of the nucleic acid which has hybridised, which may involve one or more steps of PCR or amplification of a vector in a suitable host.

Preliminary experiments may be performed by hybridising under low stringency conditions. For probing, preferred conditions are those which are stringent enough for there to be a simple pattern with a small number of hybridisations identified as positive which can be investigated further.

For example, hybridizations may be performed, according to the method of Sambrook et al. (below) using a hybridization solution comprising: 5X SSC (wherein 'SSC' = 0.15 M sodium chloride; 0.15 M sodium citrate; pH 7), 5X Denhardt's reagent, 0.5-1.0% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37-42°C for at least six hours. Following hybridization, filters are washed as follows: (1) 5 minutes at room temperature in 2X SSC and 1% SDS; (2) 15 minutes at room temperature in 2X SSC and 0.1% SDS; (3) 30 minutes - 1 hour at 37°C in 1X SSC and 1% SDS; (4) 2 hours at 42-65°C in 1X SSC and 1% SDS, changing the solution every 30 minutes.

One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology is (Sambrook et al., 1989):

$$T_m = 81.5^{\circ}\text{C} + 16.6\text{Log} [\text{Na}^+] + 0.41 (\% \text{ G+C}) - 0.63 (\% \text{ formamide}) - 600/\#\text{bp in duplex}$$

As an illustration of the above formula, using $[Na^+] = [0.368]$ and 50-% formamide, with GC content of 42% and an average probe size of 200 bases, the T_m is 57°C. The T_m of a DNA duplex decreases by 1 - 1.5°C with every 1% decrease in homology.

Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42°C. Such a sequence would be considered substantially homologous to the nucleic acid sequence of the present invention.

It is well known in the art to increase stringency of hybridisation gradually until only a few positive clones remain. Other suitable conditions include, e.g. for detection of sequences that are about 80-90% identical, hybridization overnight at 42°C in 0.25M Na_2HPO_4 , pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 55°C in 0.1X SSC, 0.1% SDS. For detection of sequences that are greater than about 90% identical, suitable conditions include hybridization overnight at 65°C in 0.25M Na_2HPO_4 , pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 60°C in 0.1X SSC, 0.1% SDS.

Thus this aspect of the present invention includes a nucleic acid including or consisting essentially of a nucleotide sequence of complementary to a nucleotide sequence hybridisable with any encoding sequence provided herein. Another way of looking at this would be for nucleic acid according to this aspect to be hybridisable with a nucleotide sequence complementary to any encoding sequence provided herein.

In a further embodiment, hybridisation of nucleic acid molecule to a variant may be determined or identified indirectly, e.g. using a nucleic acid amplification reaction, particularly the polymerase chain reaction (PCR). PCR requires the use of two primers to specifically amplify target nucleic acid, so preferably two nucleic acid molecules with sequences characteristic of VRN1 are employed. Using RACE PCR, only one such primer may be needed (see "PCR protocols; A Guide to Methods and Applications", Eds. Innis et al, Academic Press, New York, (1990)).

Preferred primers for amplification of conserved regions of VRN1 for use as probes to obtain genomic or cDNA clones may include any of those shown in Table 3.

For instance primers S63 and S49 may be used to amplify a VRN1 genomic region including the promoter and 3' end of the gene.

Primers V7 and V2 amplify the VRN1 cDNA ORF. Primers V6 and V15 may be used to distinguish VRN1 and RTV1.

Thus a method involving use of PCR in obtaining nucleic acid according to the present invention may include:

- (a) providing a preparation of plant nucleic acid, e.g. from a seed or other appropriate tissue or organ,
- (b) providing a pair of nucleic acid molecule primers useful in (i.e. suitable for) PCR, ~~at least one of said primers being a~~
- primer according to the present invention as discussed above,
- (c) contacting nucleic acid in said preparation with said primers under conditions for performance of PCR,
- (d) performing PCR and determining the presence or absence of an amplified PCR product. The presence of an amplified PCR product may indicate identification of a variant.

In all cases above, if need be, clones or fragments identified in the search can be extended. For instance if it is suspected that they are incomplete, the original DNA source (e.g. a clone library, mRNA preparation etc.) can be revisited to isolate missing portions e.g. using sequences, probes or primers based on that portion which has already been obtained to identify other clones containing overlapping sequence.

If a putative naturally occurring homologous sequence is identified, its role in vernalisation can be confirmed, for instance by methods analogous to those used in the Examples below, or by generating mutants of the gene (e.g. by screening the available insertional-mutant collections) and analyzing these for their ability to respond to vernalization, possibly in the presence and absence of other alleles such as *vrn1*. Alternatively the role can be inferred from mapping *vrn* mutants to see if the homologue lies at or close to an appropriate locus.

In a further embodiment, antibodies raised to a VRN1 polypeptide or peptide can be used in the identification and/or isolation of variant polypeptides, and then their encoding genes. Thus, the present invention provides a method of identifying or isolating VRN1 or variant thereof, comprising screening candidate polypeptides with a polypeptide comprising the antigen-binding domain of an antibody (for example whole antibody or a fragment thereof) which is able to bind said VRN1 polypeptide or variant thereof, or preferably has binding specificity for such a polypeptide. Methods of obtaining

antibodies are described hereinafter.

5 Candidate polypeptides for screening may for instance be the products of an expression library created using nucleic acid derived from an plant of interest, or may be the product of a purification process from a natural source. A polypeptide found to bind the antibody may be isolated and then may be subject to amino acid sequencing. Any suitable technique may
10 ~~be used to sequence the polypeptide either wholly or partially~~ (for instance a fragment of the polypeptide may be sequenced). Amino acid sequence information may be used in obtaining nucleic acid encoding the polypeptide, for instance by designing one or more oligonucleotides (e.g. a degenerate pool of oligonucleotides) for use as probes or primers in
15 hybridization to candidate nucleic acid.

20 This aspect of the invention further includes an isolated nucleic acid comprising a sequence which is complementary to any of those isolated or obtained as above.

As used hereinafter, unless the context demands otherwise, the term "VRN1" is intended to cover any of the nucleic acids of the invention described above, including functional variants.

25 In one aspect of the present invention, the VRN1 nucleic acid described above is in the form of a recombinant and preferably replicable vector.

30 "Vector" is defined to include, inter alia, any plasmid, cosmid, phage or *Agrobacterium* binary vector in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable, and which can transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous
35 replicating plasmid with an origin of replication).

40 Generally speaking, those skilled in the art are well able to construct vectors and design protocols for recombinant gene expression. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for example, *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et al,
45 1989, Cold Spring Harbor Laboratory Press or *Current Protocols*

in *Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992.

Specifically included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from actinomycetes and related species, bacteria and eucaryotic (e.g. higher plant, mammalian, yeast or fungal cells).

A vector including nucleic acid according to the present invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome.

Preferably the nucleic acid in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in a host cell such as a microbial, e.g. bacterial, or plant cell. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell

By "promoter" is meant a sequence of nucleotides from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA).

"Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.

In a preferred embodiment, the promoter is an inducible promoter.

The term "inducible" as applied to a promoter is well understood by those skilled in the art. In essence, expression under the control of an inducible promoter is "switched on" or increased in response to an applied stimulus. The nature of the stimulus varies between promoters. Some inducible promoters cause little or undetectable levels of expression (or no expression) in the absence of the appropriate stimulus. Other

inducible promoters cause detectable constitutive expression in the absence of the stimulus. Whatever the level of expression is in the absence of the stimulus, expression from any inducible promoter is increased in the presence of the correct stimulus.

Thus this aspect of the invention provides a gene construct, preferably a replicable vector, comprising a promoter ~~(optionally inducible) operably linked to a nucleotide sequence~~ provided by the present invention, such as the VRN1 gene or a variant thereof.

Particularly of interest in the present context are nucleic acid constructs which operate as plant vectors. Specific procedures and vectors previously used with wide success upon plants are described by Guerineau and Mullineaux (1993) (Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148). Suitable vectors may include plant viral-derived vectors (see e.g. EP-A-194809).

Suitable promoters which operate in plants include the Cauliflower Mosaic Virus 35S (CaMV 35S). Other examples are disclosed at pg 120 of Lindsey & Jones (1989) "Plant Biotechnology in Agriculture" Pub. OU Press, Milton Keynes, UK. The promoter may be selected to include one or more sequence motifs or elements conferring developmental and/or tissue-specific regulatory control of expression. Inducible plant promoters include the ethanol induced promoter of Caddick et al (1998) Nature Biotechnology 16: 177-180.

If desired, selectable genetic markers may be included in the construct, such as those that confer selectable phenotypes such as resistance to antibiotics or herbicides (e.g. kanamycin, hygromycin, phosphinotricin, chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate).

The present invention also provides methods comprising introduction of such a construct into a plant cell or a microbial cell and/or induction of expression of a construct within a plant cell, by application of a suitable stimulus e.g. an effective exogenous inducer.

In a further aspect of the invention, there is disclosed a host cell containing a heterologous construct according to the

present invention, especially a plant or a microbial cell.

The term "heterologous" is used broadly in this aspect to indicate that the gene/sequence of nucleotides in question (e.g. encoding VRN1) have been introduced into said cells of the plant or an ancestor thereof, using genetic engineering, i.e. by human intervention. A heterologous gene may replace an endogenous equivalent gene, i.e. one which normally performs the same or a similar function, or the inserted sequence may be additional to the endogenous gene or other sequence. Nucleic acid heterologous to a plant cell may be non-naturally occurring in cells of that type, variety or species. Thus the heterologous nucleic acid may comprise a coding sequence of or derived from a particular type of plant cell or species or variety of plant, placed within the context of a plant cell of a different type or species or variety of plant. A further possibility is for a nucleic acid sequence to be placed within a cell in which it or a homologue is found naturally, but wherein the nucleic acid sequence is linked and/or adjacent to nucleic acid which does not occur naturally within the cell, or cells of that type or species or variety of plant, such as operably linked to one or more regulatory sequences, such as a promoter sequence, for control of expression.

The host cell (e.g. plant cell) is preferably transformed by the construct, which is to say that the construct becomes established within the cell, altering one or more of the cell's characteristics and hence phenotype e.g. with respect to a vernalisation response.

Nucleic acid can be introduced into plant cells using any suitable technology, such as a disarmed Ti-plasmid vector carried by *Agrobacterium* exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711 - 87215 1984), particle or microprojectile bombardment (US 5100792, EP-A-444882, EP-A-434616) microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) *Plant Tissue and Cell Culture*, Academic Press), electroporation (EP 290395, WO 8706614 Gelvin Debeyser) other forms of direct DNA uptake (DE 4005152, WO 9012096, US 4684611), liposome mediated DNA uptake (e.g. Freeman et al. *Plant Cell Physiol.* 29: 1353 (1984)), or the vortexing method (e.g. Kindle, *PNAS U.S.A.* 87: 1228 (1990d) Physical methods for the transformation of plant cells are reviewed in Oard, 1991, *Biotech. Adv.* 9: 1-11.

Agrobacterium transformation is widely used by those skilled in the art to transform dicotyledonous species.

5 Recently, there has also been substantial progress towards the routine production of stable, fertile transgenic plants in almost all economically relevant monocot plants (see e.g. Hiei et al. (1994) *The Plant Journal* 6, 271-282)). Microprojectile bombardment, electroporation and direct DNA uptake are preferred where Agrobacterium alone is inefficient or
10 ineffective. Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, eg bombardment with Agrobacterium coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with
15 Agrobacterium (EP-A-486233).

Preferred transformation protocols for brassicas, wheat, barley and rice may be found Becker et al., 1994 and references therein. However the skilled person will appreciate that the
20 particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person practising the invention with a particular methodology of choice.

25 Thus a further aspect of the present invention provides a method of transforming a plant cell involving introduction of a construct as described above into a plant cell and causing or allowing recombination between the vector and the plant cell
30 genome to introduce a nucleic acid according to the present invention into the genome.

The invention further encompasses a host cell transformed with nucleic acid or a vector according to the present invention
35 (e.g comprising the VRN1 sequence) especially a plant or a microbial cell. In the transgenic plant cell (i.e. transgenic for the nucleic acid in question) the transgene may be on an extra-genomic vector or incorporated, preferably stably, into the genome. There may be more than one heterologous nucleotide
40 sequence per haploid genome.

Generally speaking, following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf discs, as is standard in the art. Almost any plant can be
45 entirely regenerated from cells, tissues and organs of the

plant. Available techniques are reviewed in Vasil et al., *Cell Culture and Somatic Cell Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications*, Academic Press, 1984, and Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989.

The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed in Shimamoto, K. (1994) *Current Opinion in Biotechnology* 5, 158-162.; Vasil, et al. (1992) *Bio/Technology* 10, 667-674; Vain et al., 1995, *Biotechnology Advances* 13 (4): 653-671; Vasil, 1996, *Nature Biotechnology* 14 page 702).

Plants which include a plant cell according to the invention are also provided.

In addition to the regenerated plant, the present invention embraces all of the following: a clone of such a plant, seed, selfed or hybrid progeny and descendants (e.g. F1 and F2 descendants). The invention also provides a plant propagule from such plants, that is any part which may be used in reproduction or propagation, sexual or asexual, including cuttings, seed and so on. It also provides any part of these plants, which in all cases include the plant cell or heterologous VRN1 DNA described above.

A plant according to the present invention may be one which does not breed true in one or more properties. Plant varieties may be excluded, particularly registrable plant varieties according to Plant Breeders' Rights.

A further aspect of the present invention provides a method for assessing the vernalisation responsiveness of a plant, the method comprising the step of determining the presence and/or identity of a VRN1 allele therein comprising the use of a nucleic acid as described above. Such a diagnostic test may be used with transgenic or wild-type plants. The use of diagnostic tests for alleles allows the researcher or plant breeder to establish, with full confidence and independent from time consuming biochemical tests, whether or not a desired allele is present in the plant of interest (or a cell thereof), whether the plant is a representative of a collection of other genetically identical plants (e.g. an inbred variety or cultivar) or one individual in a sample of related (e.g.

breeders' selection) or unrelated plants.

5 The method may form part of a plant breeding scheme based on selection and selfing of desirable individuals. Reliable selection for appropriate VRN1 alleles can be made in early generations and on more material than would otherwise be possible. This gain in reliability of selection plus the time saving by being able to test material earlier and without
10 ~~costly phenotype screening is of considerable value in plant breeding.~~

15 Nucleic acid-based determination of the presence or absence of one or more desirable alleles may be combined with determination of the genotype of the flanking linked genomic DNA and other unlinked genomic DNA using established sets of markers such as RFLPs, microsatellites or SSRs, AFLPs, RAPDs etc. This enables the researcher or plant breeder to select for not only the presence of the desirable allele but also for individual plant or families of plants which have the most
20 desirable combinations of linked and unlinked genetic background. Such recombinations of desirable material may occur only rarely within a given segregating breeding population or backcross progeny. Direct assay of the locus as afforded by the present invention allows the researcher to make a step-wise approach to fixing (making homozygous) the desired combination of flanking markers and alleles, by first
25 identifying individuals fixed for one flanking marker and then identifying progeny fixed on the other side of the locus all the time knowing with confidence that the desirable allele is
30 still present.

35 The present disclosure provides sufficient information for a person skilled in the art to obtain genomic DNA sequence for any given new or existing allele and devise a suitable nucleic acid- and/or polypeptide-based diagnostic assay. In designing a nucleic acid assay account is taken of the distinctive variation in sequence that characterizes the particular variant allele (see e.g. Fig 7 and the allelic variations described therein).

40 The invention further provides a method of influencing or affecting the vernalisation response in a plant, the method including causing or allowing expression of a heterologous VRN1 nucleic acid sequence as discussed above within the cells of
45 the plant. The method may include the use of VRN1 nucleic acid

in conjunction with other genes affecting vernalisation (e.g. VRN2). As discussed in the Examples below, VRN1 and VRN2 may act in separate and partially redundant vernalization-promoting pathways.

The step may be preceded by the earlier step of introduction of the VRN1 nucleic acid into a cell of the plant or an ancestor thereof. In addition to use of the nucleic acids of the present invention for production of functional VRN1

polypeptides (thereby enhancing the vernalisation response), the information disclosed herein may also be used to reduce the activity VRN1 activity in cells in which it is desired to do so (thereby inhibiting or destroying the vernalisation response).

For instance down-regulation of expression of a target gene may be achieved using anti-sense technology.

In using anti-sense genes or partial gene sequences to down-regulate gene expression, a nucleotide sequence is placed under the control of a promoter in a "reverse orientation" such that transcription yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene. See, for example, Rothstein et al, 1987; Smith et al, (1988) *Nature* 334, 724-726; Zhang et al, (1992) *The Plant Cell* 4, 1575-1588, English et al., (1996) *The Plant Cell* 8, 179-188. Antisense technology is also reviewed in Bourque, (1995), *Plant Science* 105, 125-149, and Flavell, (1994) *PNAS USA* 91, 3490-3496.

An alternative to anti-sense is to use a copy of all or part of the target gene inserted in sense, that is the same, orientation as the target gene, to achieve reduction in expression of the target gene by co-suppression. See, for example, van der Krol et al., (1990) *The Plant Cell* 2, 291-299; Napoli et al., (1990) *The Plant Cell* 2, 279-289; Zhang et al., (1992) *The Plant Cell* 4, 1575-1588, and US-A-5,231,020. Further refinements of the gene silencing or co-suppression technology may be found in WO95/34668 (Biosource); Angell & Baulcombe (1997) *The EMBO Journal* 16,12:3675-3684; and Voinnet & Baulcombe (1997) *Nature* 389: pg 553.

Further options for down regulation of gene expression include the use of ribozymes, e.g. hammerhead ribozymes, which can catalyse the site-specific cleavage of RNA, such as mRNA (see e.g. Jaeger (1997) "The new world of ribozymes" *Curr Opin*

Struct Biol 7:324-335, or Gibson & Shillito (1997) "Ribozymes: their functions and strategies for their use" Mol Biotechnol 7: 242-251.)

5 The complete sequence corresponding to the coding sequence (in reverse orientation for anti-sense) need not be used. For example fragments of sufficient length may be used. It is a routine matter for the person skilled in the art to screen
10 ~~fragments of various sizes and from various parts of the coding~~ sequence to optimise the level of anti-sense inhibition. It may be advantageous to include the initiating methionine ATG codon, and perhaps one or more nucleotides upstream of the initiating codon. A further possibility is to target a conserved sequence of a gene, e.g. a sequence that is
15 characteristic of one or more genes, such as a regulatory sequence.

The sequence employed may be about 500 nucleotides or less, possibly about 400 nucleotides, about 300 nucleotides, about
20 200 nucleotides, or about 100 nucleotides. It may be possible to use oligonucleotides of much shorter lengths, 14-23 nucleotides, although longer fragments, and generally even longer than about 500 nucleotides are preferable where possible, such as longer than about 600 nucleotides, than about
25 700 nucleotides, than about 800 nucleotides, than about 1000 nucleotides or more.

It may be preferable that there is complete sequence identity in the sequence used for down-regulation of expression of a target sequence, and the target sequence, although total
30 complementarity or similarity of sequence is not essential. One or more nucleotides may differ in the sequence used from the target gene. Thus, a sequence employed in a down-regulation of gene expression in accordance with the present invention may be a wild-type sequence (e.g. gene) selected from
35 those available, or a variant of such a sequence in the terms described above. The sequence need not include an open reading frame or specify an RNA that would be translatable.

40 Thus the present invention further provides the use of a variant VRN1 nucleotide sequence, or its complement, for down-regulation of gene expression, particularly down-regulation of expression of the VRN1 gene or homologue thereof, preferably in order to inhibit or suppress the vernalisation response in a
45 plant.

Anti-sense or sense regulation may itself be regulated by employing an inducible promoter in an appropriate construct.

5 The present invention also encompasses the expression product of any of the coding VRN1 nucleic acid sequences disclosed and methods of making the expression product by expression from encoding nucleic acid therefore under suitable conditions, which may be in suitable host cells.

10 As described in the Examples, several features of VRN1 suggest that it is likely to serve as a modulator of transcription (e.g., as a "co-activator" or "co-repressor"), or in the least as a DNA-binding protein. These features include the presence of the B3 domains; the homology of a portion of region 2 with
15 c-myc, a transcription factor; the presence of a putative NLS, and the presence of putative signals for rapid protein degradation, which are common in transcription factors and other proteins of regulatory function (Chevaillier, 1993; Vierstra, 1996; Barnes and Gomes, 1995; Rechsteiner and Rogers,
20 1996; Gomes and Barnes, 1997).

The present invention also provides for the production and use of fragments of the full-length polypeptides disclosed herein, especially active portions thereof. An "active portion" of a
25 polypeptide means a peptide which is less than said full length polypeptide, but which retains an essential biological activity. In particular, the active portion retains the ability to alter vernalization response in a plant, such as *Arabidopsis thaliana*.

30 A "fragment" of a polypeptide means a stretch of amino acid residues of at least about five to seven contiguous amino acids, often at least about seven to nine contiguous amino acids, typically at least about nine to 13 contiguous amino
35 acids and, most preferably, at least about 20 to 30 or more contiguous amino acids.

40 Use of recombinant VRN1 protein, or a fragment (e.g the domains discussed above) thereof, as a DNA-binding protein, or more specifically a modulator of transcription, forms one aspect of the invention.

45 Fragments of the polypeptides may include one or more epitopes useful for raising antibodies to a portion of any of the amino acid sequences disclosed herein. Preferred epitopes are those

to which antibodies are able to bind specifically, which may be taken to be binding a polypeptide or fragment thereof of the invention with an affinity which is at least about 1000x that of other polypeptides.

5 Thus purified VRN1 protein, or a fragment or other variant thereof, e.g. produced recombinantly by expression from encoding nucleic acid therefor, may be used to raise antibodies
10 ~~employing techniques which are standard in the art.~~ Antibodies and polypeptides comprising antigen-binding fragments of antibodies may be used in identifying homologues from other plant species as discussed above.

15 Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and might be screened, preferably using
20 binding of antibody to antigen of interest.

For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, 1992, Nature 357: 80-82). Antibodies may be polyclonal or monoclonal.

25 Antibodies may be modified in a number of ways. Indeed the term "antibody" should be construed as covering any specific binding substance having a binding domain with the required specificity. Thus, this term covers antibody fragments, derivatives, functional equivalents and homologues of
30 antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or synthetic.

As an alternative or supplement to immunising a mammal, antibodies with appropriate binding specificity may be obtained
35 from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.

40 Specific binding members such as antibodies and polypeptides comprising antigen binding domains of antibodies that bind and are preferably specific for a VRN1 polypeptide or variant thereof represent further aspects of the present invention, as
45 do their use and methods which employ them.

The above description has generally been concerned with the coding parts of the VRN1 gene and variants and products thereof. Also embraced within the present invention are untranscribed parts of the gene.

Thus a further aspect of the invention is a nucleic acid molecule encoding the promoter of the VRN1 gene, which is ~~believed to be present in the sequence shown in Annex I~~ (which begins at the end of the LARS1 gene).

As described in the Examples below, The VRN1 promoter region and VRN1 intron 1 were found to contain a variety of potential binding sites including low temperature response elements; binding sites for the Arabidopsis dehydration- and ABA-responsive gene rd22; one binding site for Arabidopsis Myb2, a transcription factor involved in regulation of genes responsive to water stress; H-box and TCA-1 binding sites (that may be induced by wounding and abiotic stress); and ICE-boxes (a consensus promoter element found in several cold-inducible genes).

These control elements are likely to dictate the conditions in which expression of the VRN1 transcript is obtained. For example, VRN1 may perhaps be induced by cold and/or drought treatment, or simply by application of ABA, and use of the promoter or a part thereof for induction of transcription under any of these conditions forms one aspect of the present invention

Analysis of the upstream region will reveal control regions for gene expression including control regions common to many genes (i.e TATA and CAAT boxes) and other control regions, usually located from 1 to 10,000, such as 1 to 1000 or 50 to 500 nucleotides upstream of the start of transcription. To find minimal elements or motifs responsible for regulation, restriction enzyme or nucleases may be used to digest a nucleic acid molecule, or mutagenesis may be employed, followed by an appropriate assay (for example using a reporter gene such as luciferase) to determine promoter activity. The control region may also be mutated to identify specific subregions responsible for transcriptional control. This may be achieved by a number of techniques well known in the art as such, including DNase protection footprint assays, in which the control region is brought into contact with an extract from a cell in which the

VRN1 gene is actively expressed, and the regions of the control region which bind factors in that extract is determined.

5 Nucleic acid comprising these elements or motifs forms one part of the present invention.

"Promoter activity" is used to refer to ability to initiate transcription under appropriate conditions e.g. optionally in ~~the presence of an inducer. The level of promoter activity is~~
10 quantifiable for instance by assessment of the amount of mRNA produced by transcription from the promoter or by assessment of the amount of protein product produced by translation of mRNA produced by transcription from the promoter. The amount of a specific mRNA present in an expression system may be determined
15 for example using specific oligonucleotides which are able to hybridise with the mRNA and which are labelled or may be used in a specific amplification reaction such as the polymerase chain reaction.

20 Those skilled in the art are well aware of a multitude of possible reporter genes and assay techniques which may be used to determine promoter activity. Any suitable reporter/assay may be used and it should be appreciated that no particular choice is essential to or a limitation of the present
25 invention. Also provided is a nucleic acid construct, preferably an expression vector, including the VRN1 promoter (or active fragment or variant thereof able to promote transcription) operably linked to a heterologous gene, e.g. a coding sequence, which is preferably not the coding sequence
30 with which the promoter is operably linked in nature.

The invention will now be further described with reference to the following non-limiting Figures and Examples. Other
35 embodiments of the invention will occur to those skilled in the art in the light of these.

FIGURES & SEQUENCE ANNEXES

40 Fig 1: Vernalization phenotype of vrn1 mutant under LDs and SDs; vernalization phenotype of vrn1-1 allele compared to vrn1-2 allele.

45 Fig 2: Genetic map of the position of VRN1 on chromosome III in relation to markers used for mapping. The markers (shown on right) were scored on a population of 494 F2 plants from a

cross between *vrn1-1 fac1* x *fca-10*. The distance in cM between each marker is shown on the left.

Fig 3: Physical map of the region containing *VRN1*.

Fig 4: Complementation of the *vrn1-1* mutant phenotype by cosmids 8H8 and 10F10. Following vernalization, *fca-1* plants flower early and *vrn1-1 fca-1* plants flower late.

~~Representative T2 lines in which cosmid 8H8 or 10F10 has been~~
transformed in *vrn1-1 fca-1* plants show the expected ratio (approx. 3:1) of early-to-late flowering plants.

Fig 5: Sequenced region, and predicted ORFs in the vicinity of *VRN1*. Overlap between cosmids was initially determined by *Xba*I + *Xho*I digestion and Southern blotting. Sequencing of cosmid DNA confirmed these results and revealed the complementing region as 6565 bp. ORF1 was subsequently shown to be *VRN1*.

Fig 6: Structure of the *VRN1* gene and transcript, and positions of the *vrn1-1* and *vrn1-2* mutations.

Fig 7: The putative *VRN1* transcript and its deduced amino acid sequence.

Fig 8: Alignment of *VRN1* and *RTV1*

Fig 9: Southern blot of genomic DNA from various cereals probed with *VRN1* cDNA

Annex I: this shows contig 29 [bp 1501-6500]) derived from Ler *VRN1* genomic DNA. The *VRN1* promoter is present in the region between about nucleotides 1 to 1879.

EXAMPLES

Example 1 - Isolation of the *vrn1* mutants

The *vrn1* mutation was selected from mutagenized populations of *Arabidopsis thaliana* (L.) Heynh (Landsberg erecta ecotype) plants on the basis of its impairment of the acceleration of flowering following a six week cold treatment (vernalization). Mutants were subsequently analyzed for flowering time in the absence of vernalization in order to confirm that the induced defect was specific to the process of vernalization and not due

to a general late-flowering mutation (Chandler et al., 1996).

Two recessive alleles of *vrn1* have been identified: (1) *vrn1-1* was isolated by mutagenising *fca-1* seeds with EMS, as described (Chandler et al., 1996), and (2) *vrn1-2* was isolated by mutagenising *fca-1* seeds with gamma irradiation. The *vrn1-1 fca-1* line used here was backcrossed to *fca-1* two times prior to genetic mapping. Subsequently, *vrn1-1 fca-1* was further backcrossed to *fca-1* (six times in total) and *vrn1-2 fca-1* was backcrossed two times in total.

Example 2 - Characterization of the *vrn1* phenotype

The vernalization dose-response phenotype of *vrn1* mutant plants was investigated by examining their flowering time in response to differing durations of vernalization treatment. Flowering time was measured in two ways: (1) as the total number of vegetative leaves produced prior to flowering (LN), and (2) as the time in days from the end of the vernalization treatment to the appearance of the first floral bud (FT). In all experiments these two measures were positively correlated, so only LN is given in order to more easily facilitate comparison between experiments.

Two types of experiment were conducted: (1) a dose-response analysis of *vrn1-1 fca-1* and *vrn1-2 fca-1* examined under long day (LD) growth conditions (Figure 1A), and (2) the effect of 6 weeks of vernalization on *vrn1-1* in the absence of *fca-1* examined under short day (SD) growth conditions (Figure 1B). In the LD experiment shown in Figure 1A, with no vernalization (0 weeks), both *vrn1-1 fca-1* and *vrn1-2 fca-1* mutant plants flowered very slightly earlier compared to the parental *fca-1* controls, although in other experiments *vrn1-1 fca-1* and *vrn1-2 fca-1* mutant plants flowered at approximately the same time as *fca-1* with no vernalization. In contrast, following vernalization, *fca-1* plants showed a marked reduction in leaf number ($\approx 66\%$ after 6 weeks of vernalization), while *vrn1-1 fca-1* and *vrn1-2 fca-1* mutant plants showed a much reduced response ($\approx 14\%$ and $\approx 27\%$ after 6 weeks of vernalization, respectively). Therefore, both alleles of *vrn1* are dramatically impaired in their response to vernalization, with *vrn1-1* being more severe than *vrn1-2*.

In the SD experiment shown in Figure 1B, the wild type Ler

plants exhibited a $\approx 49\%$ reduction in leaf number after a vernalization treatment of six weeks compared to unvernallized plants. However, *vrn1-1* mutant plants showed only a $\approx 18\%$ reduction under the same conditions. In addition, this experiment shows that the phenotype of *vrn1-1* does not depend on the presence of the *fca-1* mutation or on long day photoperiods. *vrn1-1* was also combined with other late flowering, vernalization-responsive mutations (*fve-1*, *ld-3*, *fwa-1*, *fe-1*, *fpa-2*, and *ft-1*) and was shown to impair the vernalization response of these mutants as well (Chandler et al., 1996).

Example 3 - Genetic mapping of VRN1

The *VRN1* gene was initially mapped to the top arm of chromosome III, between RLFP markers mi207 and mi339, using a relatively small F2 population (77 plants) derived from a cross between *vrn1-1 fca-1* and *fca-10*, as described (Chandler et al., 1996). A larger population (494 F2 plants) derived from the same cross was then used to finely map the position of *VRN1* (Figure 2). The dearth of available genetic markers in this region necessitated the development of several new genetic markers that were polymorphic between the Ler and Ws ecotypes (Table 1). As a first step, two markers flanking *VRN1*, ATHCHIB (SSLP) and g4711 (CAPS) were used to screen the population for recombinants in this ≈ 18 cM interval. Approximately 170 recombinant chromosomes were identified. Next, the markers indicated in Figure 2 were used with these recombinants to define the position of *VRN1* to the ≈ 0.5 cM interval between mi339 (2 recombinants to the north) and pKS1240 (one recombinant to the south). The CAPS marker agp14, corresponding to a dioxygenase gene, was genetically inseparable from *VRN1* (Figure 2).

Example 4 - Physical mapping of VRN1

The interval between mi339 and pKS1240 fell in a gap between Contig 3 and Contig 4 of the CIC YAC coverage of chromosome III (Camilleri et al., 1998) so therefore no physical map data was available. Initially, an attempt was made to fill the gap using YAC clones other than those derived from the CIC library (i.e., yUP, EW, and EG), but this genomic region was apparently not represented in any of these libraries. Therefore, a physical map of the interval was constructed using IGF (Mozo et al.,

1998) and TAMU (<http://genome-www.stanford.edu/Arabidopsis/ww/Vol2/choi.html>) BAC clones. Marker mi339 was used to screen the BAC libraries and to initiate a walk towards pKS1240. BAC contigs (Figure 3) were assembled by hybridizing BACs to end probes developed by iPCR (Table 2) and by using publicly available BAC end sequence data (from TIGR; http://www.tigr.org/tdb/at/atgenome/bac_end_search/bac_end_search.html) as the basis for designing oligonucleotide primers for PCR (Table 2). The size of individual BAC clones was determined by hexagonal pulsed-field gel electrophoresis (Maule, 1997). The ≈ 0.5 cM interval between mi339 and pKS1240 containing the VRN1 gene was therefore found to correspond to ≈ 120 kb of genomic DNA.

In preparation for cosmid complementation experiments, a Ler genomic library in the cosmid 04541 binary vector (Macknight et al., 1997) was initially screened using the following probes: BAC T24F13, mi339, agp14, and pKS1240. Putative positive clones were verified on Southern blots and the overlap between individual cosmids determined by either hybridization with DNA probes or with PCR primers designed from BAC- and cosmid- end sequence data (Table 2). The insert sizes of individual cosmid clones was determined by digestion with XbaI + XhoI followed by standard agarose gel electrophoresis using lambda DNA cut with HindIII as a standard. A complete cosmid contig was generated over the ≈ 120 kb region (Figure 3).

Example 5 - Cosmid complementation of the *vrn1* phenotype

Eight cosmids (39K3, 8H8, 10F10, 42A10, 2P5, 19D3, 27J7, 67N6) centered around the marker agp14 were transformed into *vrn1-1 fca-1* plants by *Agrobacterium tumefaciens*-infection of root tissue (Hooykaas, 1989). In order to test if any of these cosmids rescued the mutant phenotype of *vrn1-1 fca-1*, T2 seed (from individual T1 kanamycin resistant transformants) was sown on soil and vernalized for 5 weeks. Seedlings were then transferred to LD conditions, and pricked out into individual compartments of divided trays after about a week of growth. The total leaf number prior to flowering was determined, and cosmids were scored as complementing if the segregation ratio of early to late plants (compared to *fca-1* and *vrn1-1 fca-1* controls) was approximately 3:1 or greater. Eight independent lines containing cosmid 8H8, eight independent lines containing cosmid 10F10, and three independent lines containing cosmid

39K3 were found to rescue mutant phenotype of *vrn1-1 fca-1*. Lines containing the other five cosmids did not complement the *vrn1-1* phenotype (Figure 3). Analysis of the flowering time segregation in typical 8H8 and 10F10 complementing lines is shown in Figure 4. The presence of each cosmid in complementing lines (T2 plants) was confirmed by a cosmid-specific diagnostic

PCR, comprising an insert specific primer 8H8DIAG1
(ACCTGCTTCTGCCAACCGCTC) and 10F10DIAG1

(AGTTCGCTCTTGCTGTTTTTTTCCC) (corresponding to a portion of the Ler genomic DNA) and a primer BACT 7U (CCTCTTCGCTATTACGCCAG) present in the cosmid vector (see "cosmid complementation" under "materials and methods" below).

Example 6 - Analysis of genomic DNA corresponding to the complementing region

(a) Sequencing of cosmid DNA

The region of chromosome III corresponding to the cosmid contig surrounding VRN1 (Figure 3) had apparently not previously been sequenced. Therefore the insert DNA from cosmids 8H8, 10F10, and 39K3 (derived from Ler genomic DNA) was sequenced by a combination of primer walking and shotgun strategies (Table 3), resulting in three contigs of sequence (Figure 5). The total amount of new *Arabidopsis* genomic sequence obtained was 20950 bp.

(B) Identification of candidate ORFs in genomic sequence

As new genomic sequence data was obtained it was analyzed in several ways in order to identify potential open reading frames (ORFs) and genes. Firstly, homology searches were carried out using the BLAST and FASTA computer programs available from the *Arabidopsis thaliana* Database (AtDB; <http://genome-www.stanford.edu/Arabidopsis/seqtools.html>) and National Center for Biotechnology Information (NCBI; <http://www.ncbi.nlm.nih.gov/BLAST/>). Using these programs, genomic sequence in the VRN1 region was compared (1) the *Arabidopsis* EST database, and (2) the database of all non-redundant Genbank sequences. Secondly, searches were carried out using the NetPlantGene (<http://www.cbs.dtu.dk/NetPlantGene.html>), BCM Gene Finder

(<http://dot.imgen.bcm.tmc.edu:9331/gene-finder/gf.html>), and GENESCAN (<http://gnomic.stanford.edu/GENSCANW.html>) computer programs which are designed to recognize features of eukaryotic genes, such as intron-exon boundaries, ORFs and polyadenylation signals. The results of these analyses are summarized in Figure 5 ("Predicted ORFs"). The sequenced region (contigs 29, 2, and 4) was found to contain ≈ 8 potential genes. Three of these, *agp14*, *LARS1*, and *ORF1* (later identified as *VRN1*) were represented by ESTs in the GenBank EST database.

Example 7 - Identification of the *vrn1-1* and *vrn1-2* mutations and determination of the *VRN1* gene structure

*(A) Finding mutations in *vrn1* mutant plants*

The three cosmids which rescued the *vrn1-1 fca-1* mutant phenotype (8H8, 10F10, 39K3) were subjected to restriction analysis using *Xba*I and *Xho*I (Figure 5) and the region of overlap between these three cosmids found to be ≈ 6.5 kb. The ORF analysis indicated that this 6.5 kb interval contained the 3' end of the *LARS1* gene (a dioxygenase closely related to *agp14*), the 3' end of a hypothetical gene of unknown function, and the entire structure of another gene, "ORF1" (Figure 5).

In order to determine if either *LARS1* or *ORF1* corresponded to *VRN1*, a search for the presence of mutations in these genes in *vrn1-1 fca-1* and *vrn1-2 fca-1* mutant plants was carried out. PCR primers initially used in the sequencing of cosmid DNA (Table 3) were now used to amplify products from *vrn1-1 fca-1* and *vrn1-2 fca-1* genomic DNA. Overlapping products that encompassed the entire predicted ORF of *LARS1* and *ORF1* were sequenced on both strands and compared to the Ler-derived cosmid sequence for the presence of differences corresponding to mutations. No mutations were found in the *LARS1* gene, but in *ORF1*, a 1bp nonsense mutation was found in *vrn1-1 fca-1*-derived DNA and a 1bp deletion was found in *vrn1-2 fca-1*-derived DNA (Figure 6). Each of these putative mutations were then confirmed by sequencing four more independent PCR products on both strands. The effect of the *vrn1-1* and *vrn1-2* mutations on the encoded *VRN1* protein is described in Example 8.

*(B) Determining the structure of the *VRN1* gene*

The structure of the *VRN1* gene and putative transcript was

determined by a combination of (1) RT-PCR analysis, (2) 3'-RACE analysis, and (3) analysis of partial cDNA clones represented in the GenBank *Arabidopsis* EST database (Table 4). These techniques revealed the sequence of the *VRN1* transcript and by comparing this sequence with the *VRN1* genomic sequence, the intron/exon boundaries were determined (Figure 6, Figure 7). The results obtained by these approaches were all in agreement, i.e., the intron-exon boundaries and point of polyadenylation determined by RT-PCR and 3'-RACE were identical to those determined through analysis of EST clones corresponding to *VRN1* cDNA, although the 5' transcription start site of the *VRN1* gene was not definitively determined by the experiments. Within the putative *VRN1* transcript (Figure 7), the Ler-derived sequence obtained by RT-PCR and the Columbia-derived sequence obtained by the sequencing of EST clones were 100% identical.

The *VRN1* gene is comprised of 5 exons and covers ≈ 3.0 kb of genomic DNA from the putative transcription start to the point of polyadenylation (see Annex I). Introns 2, 3, and 4 are a typical size for an *Arabidopsis* gene (≈ 100 bp), while intron 1 is quite large: ≈ 1.2 kb (Figure 6). The 5- and 3-UTR of the *VRN1* transcript are also somewhat larger than average: ≈ 270 and ≈ 200 bp, respectively (Figures 6, 7).

The *VRN1* promoter region (from end of *LARS1* gene to *VRN1* translation initiation codon) and *VRN1* intron 1 were analyzed for binding sites of known plant transcription factors and known promoter elements using the Web Signal Scan program and PLACE database

(<http://www.dna.affrc.go.jp/htdocs/PLACE/signalscan.html>).

These regions of *VRN1*, which may potentially specify the expression of the *VRN1* gene, were found to contain the following potential binding sites: (1) two low temperature response elements (LTREs; also known as CRT/DREs), found in several cold-induced genes from *Arabidopsis*, *Brassica napus*, and barley and bound by the transcription factor CBF1 (Baker et al., 1994; Stockinger et al., 1997; Jiang et al., 1996; Nordin et al., 1993), (2) three binding sites for the *Arabidopsis* dehydration- and ABA-responsive gene *rd22* (Abe et al., 1997), (3) one binding site for *Arabidopsis* *Myb2*, a transcription factor involved in regulation of genes responsive to water stress (Urao et al., 1993), (4) one H-box and three TCA-1 binding sites, promoter elements found in several tobacco, barley, and bean (*P. vulgaris*) genes that are induced by

wounding and abiotic stress (Loake et al., 1992; Mhiri et al., 1997; Goldsbrough et al., 1993), and (5) three ICE-boxes, a consensus promoter element found in several cold-inducible genes (G.J. Warren, unpublished). It is interesting that control elements for both cold- and drought-inducible genes are present within the *VRN1* promoter and intron 1, as these conditions are known to induce several genes involved in acclimation to freezing temperatures (Thomashow, 1994), and ABA signaling is involved (Gilmour and Thomashow, 1991). These control elements are likely to dictate the conditions in which expression of the *VRN1* transcript is obtained. For example, *VRN1* may perhaps be induced by cold and/or drought treatment, or simply by application of ABA.

Taken together, the presence of mutations within *ORF1* (the only predicted gene that was completely contained within the complementing region) in genomic DNA derived from *vrn1-1* and *vrn1-2* mutant plants confirmed that *ORF1* corresponds to the *VRN1* gene.

This may be readily confirmed by introduction of the ORF (in sense and antisense) into *Arabidopsis* (cf. Example 5 above). Constructs may be based on the pGreen0029 vector which drives expression of the cloned in gene with a double 35S promoter and terminator derived from CaMV. This vector, and how to obtain it, is discussed in detail in WO 99/27120 (Plant Bioscience Limited).

(1) Genomic sense construct: the unspliced (genomic) *VRN1* ORF in the sense orientation in order to produce high levels of functional *VRN1* product. This construct will be put into *vrn1-1 fca-1* and *vrn1-2 fca-1* plants.

(2) cDNA sense construct: the spliced (cDNA) *VRN1* ORF in the sense orientation in order to produce high levels of functional *VRN1* product. This construct will be put into *vrn1-1 fca-1* and *vrn1-2 fca-1* plants.

(3) cDNA antisense construct: the spliced (cDNA) *VRN1* ORF in the antisense orientation in order to repress the normal expression of *VRN1* and diminish the amount of functional *VRN1* product. This construct will be put into *fca-1* and Ler plants.

As an alternative to a constitutive promoter, it may be

desirable to use an inducible promoter, such as one which is controlled by application of the molecule dexamethasone.

Example 8 - Analysis of the putative protein encoded by the VRN1 gene

The deduced amino acid sequence of VRN1 (Figure 7) was compared with the entire GenBank database (NCBI) using the BLASTP and TBLASTN programs.

(A) VRN1: domain structure, sequence features, and similarity to other known and hypothetical sequences

The VRN1 gene encodes a putative protein of 341aa (calculated MW=39278 Da) that is basic (pI=9.1), and is comprised of at least three regions. Region 1 (residues 2-94 in Figure 7) and 3 (residues 239-332) which are homologous to each other and are related to the B3 DNA-binding domain originally found in the maize transcription factor VIVIPAROUS1 (VP1; McCarty et al., 1991). Domains similar to the B3 domain of VP1 have subsequently been found in several *Arabidopsis* transcription factors or putative transcription factors such as ABI3 (the *Arabidopsis* orthologue of maize VP1, (Giraudat et al., 1992), auxin response factors (Ulmasov et al., 1997), IAA response factors (Kim et al., 1997; Abel et al., 1994; Guilfoyle et al., 1998), FUSCA3 (Luerksen et al., 1998), and RAVs (Kagaya et al., 1999). Several of these proteins have been shown to bind DNA in sequence-specific manner via their B3 domain (e.g., Kagaya et al., 1999; Suzuki et al., 1997; Ulmasov et al., 1997).

The B3 DNA-binding domain appears to be specific to plants (Suzuki et al., 1997), and analysis of translated nucleotide sequences (i.e., hypothetical proteins) in the GenBank databases has revealed at least 22 *Arabidopsis* sequences that contain B3 domains, as well as EST sequences from several other plant species such as *Brassica oleracea*, hybrid aspen (*Populus tremula* x *P. tremuloides*), and tomato. While VRN1 contains two B3 domains, most characterized and hypothetical amino acid sequences were found to contain only one B3 domain, and some were found to contain more than two. The B3 domain appears to be "defined" by a number of conserved positions (results not shown) rather than sequence identity over the whole domain. Therefore, BLAST scores between the sequences shown tested are only marginally significant (on the order of 10^{-6} to 10^{-1}).

The C-terminal portion of the B3 domain is more conserved than the N-terminal portion.

Phylogenetic analysis of B3 domains (results not shown) using the Clustal method suggests that *Arabidopsis* B3-containing proteins fall into several groups: (1) ABI3- and FUSCA3-like B3s, (2) auxin response factor- (ARFs) and IAA-inducible protein-like B3s, (3) RAV1-like B3s, and (4) at least four uncharacterized groups, which include the VRN1-like B3s. It is likely that through evolution the B3 domain has been recruited in different ways by proteins involved in diverse plant processes.

Region 2 of VRN1 (residues 95-238), which lies between the two B3 domains (Figure 7), is not obviously related to any domain of known function, nor does it have obvious features of a transcriptional activation or repression domain. Nonetheless, region 2 does contain several sequence features and motifs of interest, including a putative nuclear localization signal (NSL), two putative PEST regions (identified using the PEST Sequence Utility (<http://www.lif.icnet.uk/LRITu/projects/pest/>) based on Rechsteiner and Rogers, 1996; Rogers et al., 1986), and three RXXL motifs also associated with rapid protein degradation (Cooper et al., 1997) (Figure 7). Interestingly, the second PEST region of VRN1 contains a potential protein kinase C (PKC) phosphorylation site (residues 176-178 in Figure 7). There are several examples in the literature for regulation of the cellular "lifespan" of proteins by phosphorylation of PEST regions (e.g., McKinsey et al., 1997; Koepp et al., 1999; Yaglom et al., 1996; Marchal et al., 1998; Liu et al., 1997). For example, in the case of I κ B, stimulation of cell surface receptors by cytokines initiates a signal transduction cascade that phosphorylates I κ B at two specific serine residues in the PEST region, triggering the polyubiquitination of nearby lysine residues and ultimately proteolysis (McKinsey et al., 1997; Laney and Hochstrasser, 1999).

Analysis of the physiochemical characteristics of VRN1 suggest that the two B3 domains are basic (average pI \approx 9.5) and slightly hydrophobic in character, while region 2 is slightly acidic (pI \approx 6.3) and somewhat hydrophilic and therefore likely to be on the surface of the molecule and exposed to the aqueous environment. Interestingly, unlike the B3 domains which appear to be specific to plants, BLAST searches against GenBank (NCBI) with region 2 of VRN1 picked up no significant hits from plants

(except for RTV1, see below) but did reveal weak homology between the N-terminal portion of region 2 (residues 109-167) and a region of the vertebrate proto-oncogene transcription factor c-MYC (Schmidt, 1999). Furthermore, this region of c-myc lies in the linker between the DNA-binding domain and the transcriptional activation domain (Kerkhoff and Bister, 1991; Classon et al., 1993) and is not required for the oncogenic transformation activity of the protein (Stone et al., 1987). By analogy, this portion of region 2 of VRN1 may similarly serve as a linker region of no great importance to VRN1 function. Alternatively, region 2 may function as a novel type of transcriptional activation or repression domain, or in some other, unknown, function of VRN1. Table 4 gives information on the sequences which were used in comparisons with VRN1. The RTV1 gene is discussed below.

(B) Effect of the allelic mutations on VRN1

The mutations found in the two mutant alleles of *vrn1* (Figure 6) and the effect of these mutations on the resulting encoded protein can be correlated with the phenotypic severity, i.e., effect on vernalization response (Figure 1A), of the two alleles. As shown in Figure 7, the *vrn1-1* allele encodes a polypeptide of only 47 aa, and the *vrn1-2* allele encodes a polypeptide of 194 aa (the last six of which are incorrect due to a frameshift) compared to 341 aa for the wild-type protein. The fact that the polypeptide encoded by *vrn1-2* contains the first B3 domain as well as the putative PEST regions and NLS but is only slightly less severe in its effect on vernalization than the *vrn1-1* allele (Figure 1A), suggests that the second B3 DNA-binding domain may be required (but not necessarily sufficient) for VRN1 function under the conditions used.

(C) The RTV1 gene, a relative of VRN1

Despite the presence of many plant proteins that contain the B3 domain, only one putative protein sequence has been found with a domain structure identical to VRN1, i.e., containing regions 1-3 in the same configuration and with no additional domains. The gene encoding this protein, which is represented in the *Arabidopsis* EST database (Table 4), has been named RTV1 (related to VRN1). RTV1, which is on IGF BAC clone F13F21 on chromosome 1, encodes a protein of 301 aa which is very similar to VRN1 (Figure 9 and Table 5). While the overall similarity

between RTV1 and VRN1 is 74% (within the coding region), the similarity is greatest at the C-terminal end, with region 3 of RTV1 and VRN1 being 99% similar (Figure 9 and Table 5). Outside of the coding region (i.e., in the UTRs, promoter region and introns), the VRN1 and RTV1 genes appear to be unrelated. However, the intron/exon organization of the RTV1 gene is similar to VRN1 and therefore the two genes are likely to be the result of a duplication event. The most notable difference between VRN1 and RTV1 is the deletion of 33 amino acids in the first B3 domain of RTV1 (Figure 9). It is worth noting that this deletion does not affect the C-terminal, most conserved, portion of the B3 domain (Figure 9).

The finding of a gene that is very closely related to VRN1 suggests that RTV1 may serve a function in vernalization response or other aspect of flowering time control. Since the *vrn1-1* allele encodes a short polypeptide of only 47 amino acids, with no complete putative DNA-binding domain (Figure 7) it is likely to encode a non-functional polypeptide. The fact that *vrn1-1* mutant plants still retain a small response to vernalization (Figure 1) suggests the presence of other *Arabidopsis* factors that can partially substitute for VRN1 function. Since RTV1 is a closely-related VRN1 paralogue in *Arabidopsis* it may be such a factor.

Another factor that may possibly be responsible for this functional redundancy is VRN2 (Chandler et al., 1996). Like *vrn1-1 fca-1* mutants, *vrn2-1 fca-1* mutants also retain a partial response to vernalization, but *vrn1-1 vrn2-1 fca-1* triple mutants do not (data not shown). If it is assumed that *vrn1-1* is a "null" mutation, then this result suggests that VRN1 and VRN2 act in separate and partially redundant vernalization-promoting pathways.

Example 9 - Detection and isolation of VRN1-related genes from other plant species

A high-stringency Southern blot of genomic DNA from various cereals, when hybridized with a probe corresponding to the VRN1 transcript, specifically detected VRN1-related genes in millet, sorghum, barley, rice, wheat, and maize (see Figure 9).

To prepare the blot, approximately 10 μ g of genomic DNA from each of these varieties was digested with Eco RI (37°C,

overnight). DNA samples were separated by gel electrophoresis on a 0.8% agarose gel run at 50V for 16 hours. The gel was then processed for Southern blotting by standard procedures (see Maniatis, supra) and DNA was blotted overnight onto a nylon membrane (Hybond-N, Amersham). Following blotting, the DNA was cross-linked to the filter by exposure to UV light according to the manufacturer's recommendations and baked at 80°C for 2 hrs.

The *VRN1* cDNA probe V2V6 was prepared by amplifying an aliquot of the first-strand cDNA synthesis from total RNA of *Arabidopsis* seedlings with the oligonucleotide primers V2 and V6. The resulting PCR product was purified by agarose gel electrophoresis and labeled with ³²P-dCTP by the random hexamer priming method (see Maniatis, supra).

Hybridisation of the filter with the radiolabelled probe, and subsequent washes, were under standard high stringency conditions using buffer comprising 5 x SSC, 5 X Denhart's solution, and 0.5% SDS at 65°C for 16 hours. The filter was then washed sequentially in (1) 2XSSC, 0.1% SDS at room temperature for 10 minutes; (2) 1XSSC, 0.1% SDS at 65°C for 15 minutes; and (3) 0.1XSSC, 0.1% SDS at 65°C for 10 minutes.

The washed filter was exposed to a PhosphorImager plate (Molecular Dynamics) for 3 days prior to visualisation.

In the light of the results above, in addition to the monocots, it is highly probable that *VRN1*-related genes will be found to exist in agronomically important dicot species (e.g. Brassicaceae, sugarbeet, peas and celery etc.)

Thus the provision of sequence information for the *VRN1* gene of *Arabidopsis thaliana* enables the obtention of homologous sequences from cDNA or genomic libraries from other plant species, such as can be prepared or obtained by the skilled person without undue burden. Positive clones can be further analyzed by restriction endonuclease digestion and Southern blotting as described hereinbefore. Particularly preferred are homologues from commercially important species that have a vernalization requirement, or show some response to vernalization.

Materials and Methods used in Examples

Plant growth

For vernalization treatments, seeds were sown on fine grit (Levington's M3) in individual pots, and germinated for increasing durations at 4°C, 8hr light:16hr dark, 5 mmol m⁻² sec⁻¹ light intensity. For dose-response experiments seed sowing was staggered, with all plants removed from the vernalization conditions simultaneously. Following vernalization, seedlings were placed into a controlled environment chamber (Gallenkamp), 20°C, 16 hr light: 8hr dark 90 mmol m⁻² sec⁻¹ light intensity. Seedlings receiving no vernalization treatment were stratified for 2 days under vernalization conditions, and grown for two days prior to transfer in to the growth cabinet. Plants were grown for 10 days, and then pricked out into individual compartments of P40 trays. Flowering time was measured by counting total leaf number (i.e. rosette and cauline leaves) by marking the leaves with permanent black ink as they emerged.

Genetic mapping

VRN1 was initially positioned on Chromosome 3 through linkage to RFLP markers mi339 and mi207 (Liu et al., 1996), in F2 progeny (154 chromosomes) of a cross between *vrn1-1 fca-1* (Ler background) and *fca-10* (Ws background), as described in (Chandler et al., 1996). As a first step in refining this map position, two existing RFLP markers in the region (g4711 and m560B2; Chang et al., 1988), and two existing SSLP markers in the region (ATHCHIB and nga162; Bell and Ecker, 1994), were scored on a larger F2 population (988 chromosomes) of the same cross as above. In order to refine the map position of VRN1 further, new genetic markers that were polymorphic between Ler and Ws were developed (Table 1). Standard techniques (e.g., restriction digestion, ³²P-labeling of probes, agarose gel electrophoresis, Southern blotting, and PhosphorImager detection) were used throughout.

Physical mapping

YAC, BAC and cosmid clones and libraries were handled, analyzed, and hybridized according to standard procedures (Schmidt and Dean, 1995; Bent et al., 1998; Macknight et al., 1997). As with the genetic mapping of VRN1, some probes and PCR markers were existing and available, and some were developed in

order to establish or refine the overlap between clones. The following probes and PCR markers were existing and available: mi289, GBGe303, MSH2, ve039, mi339, agp14, MAP2K, sAT2105b, and m506B2. New probes and PCR markers developed in order to identify the *VRN1* gene are listed in Table 2. New probes and PCR markers were developed by three methods: (1) iPCR of BAC ends, (2) design of PCR primers based on BAC end sequence data (from TIGR; http://www.tigr.org/tdb/at/atgenome/bac_end_search/bac_end_search.html), and (3) sequencing of cosmid ends and design of PCR primers based on the obtained data.

(A) *iPCR of pBelo-BAC ends*

The following procedure is a modification of a protocol received from T. Altmann (MPI, Golm, Germany). DNA from 1/10th of a 25 ml BAC overnight culture was digested with (1) *HhaI* or *EcoRI* or *HincII* or *RsaI* for the T7 end, or (2) *HhaI* or *HaeII* or *EcoRV* for the Sp6 end, and phenol chloroform extracted and ethanol precipitated. Digested material was ligated in a 100 μ l standard reaction with T4 DNA ligase, heat inactivated, and ethanol precipitated. Ligation products were digested with *PvuI* for the T7 end, and *BsrBI* for the Sp6 end in a 15 μ l reaction volume. For PCR, 1 μ l of digestion reaction was amplified in a standard reaction using (1) primers BACT7U and BACT7L for the T7 end, or (2) primers Sp6A and Sp6B for the Sp6 end.

BACT7U	5' - CCTCTTCGCTATTACGCCAG -3'
BACT7L	5' - GCCCTTCCCAACAGTTTCG -3'
Sp6A	5' - CACACAGGAAACAGCTAT -3'
Sp6B	5' - ACACAACATACGAGCCGGAA -3'

(B) *Sequencing of cosmid DNA and PCR products*

Genomic sequence was obtained from the ends of cosmid insert DNA using the BIGDYE cycle sequencing kit (Perkin Elmer Applied Biosystems), and T3 and T7 primers, whose sequences flank the genomic DNA insert site. For sequencing regions further into the cosmid insert DNA, and for sequencing PCR products amplified off of genomic DNA from the *vrn1-1* and *vrn1-2* alleles, the oligonucleotides shown in Table 3 were used. The reactions were run on an ABI377 machine, and compiled using the SeqMan (DNASTar, Lasergene) program.

Cosmid complementation

Cosmids in the 04541 binary vector were mobilized into *Agrobacterium tumefaciens* (strain C58C1 Rif^R) by tri-parental mating (Hoekema et al., 1983). *vrn1-1 fca-1* plants were transformed with these *Agrobacterium* strains by root infection (Hooykaas, 1989). Transgenic plants were selected on GM with Kanamycin (50 mg/mL), and transferred to soil when they had reached the 3-4 leaf stage. The presence of each cosmid in the transgenic lines was confirmed using a specific diagnostic PCR reaction, using a primer present within the cosmid insert sequence and a primer present in the cosmid flanking the insert site. T2 seed were collected, and analyzed for the segregation of Kanamycin resistance or sensitivity on GM plates containing Kanamycin (as above), scored 14-20 days after germination. Lines that segregated a 3:1 ratio of resistant to sensitive plants were tested for their ability to complement the *vrn1-1* mutant phenotype, by vernalizing for 5 weeks and recording the total leaf number.

RT-PCR and 3'-RACE

In order to determine the intron-exon structure of the *VRN1* gene, RT-PCR reactions using total RNA prepared from *fca-1* and *vrn1-1 fca-1* seedlings grown on soil were performed according to standard procedures (Frohman et al., 1988). The PCR products were sequenced using both the primers used for PCR, and selected internal primers, using the BIGDYE kit (PE Applied Biosystems). The reactions were run on an ABI377 machine, and compiled using the SeqMan (DNASTar, Lasergene) program.

Sequence comparisons

The nucleic acid sequence comparison in Table 5 was by using the Jotun Hein method (weighted residue table) of MegAlign (DNASTar). Genomic and cDNA sequences were aligned using the BLAST 2 SEQUENCES program (<http://www.ncbi.nlm.nih.gov/gorf/bl2.html>) from NCBI.

Parameters are preferably set, using the defaults, as follows:

Gap penalty: 11
Gap length penalty: 3
KTUP word length: 6

Amino acid sequences were initially aligned using the Clustal

method, using the PAM 250 residue weight table, and further adjusted manually. For amino acid similarity comparisons, amino acids were grouped into five classes on the basis of physiochemical properties, as follows: (1) hydrophobic - G, A, V, P, M, I, L; (2) polar - S, T, N, Q, C; (3) bulky ring - Y, F, W, H; (4) positively charged - K, R; (5) negatively charged - D, E.

Table 1. Genetic markers developed in order to identify the *VRN1* gene.

	Marker	Type	Ler/Ws polymorphism
5	GBGe303	RFLP	SspI; Ler band < Ws band
	MSH2	CAPS	Sau3A; Ler: 2 sites, Ws: no sites BfaI; Ler: no sites, Ws: 1 site
	ve039	CAPS	RsaI; Ler: 3 sites, Ws: 2 sites
	agp14	RFLP	HpaII; Ler band < Ws band
	pKS1240	RFLP	DraI; Ler band > Ws band
10	MAP2K	RFLP	HaeIII; Ler band < Ws band

Table 2. Physical mapping markers developed in order to identify the *VRN1* gene.

	Marker	Type	Method used to develop
5	T4L24-T7	Southern probe	iPCR
	T7H5-Sp6	Southern probe	iPCR
	T15C16-Sp6	Southern probe	iPCR
	T10N5-T7	Southern probe	iPCR
10	T24F13-T7	PCR diagnostic	BAC end sequence data (public)
	8H8-T7	PCR diagnostic	cosmid end sequence (obtained)
	F25C7-T7	PCR diagnostic	BAC end sequence data (public)
	10F10-T3	PCR diagnostic	cosmid end sequence (obtained)
	8H8-T3	PCR diagnostic	cosmid end sequence (obtained)
15	F18G1-T7	PCR diagnostic	BAC end sequence data (public)
	10F10-T7	PCR diagnostic	cosmid end sequence (obtained)
	T4L24-Sp6	PCR diagnostic	BAC end sequence data (public)
	T20A21-Sp6	Southern probe	iPCR
	T7H5-T7	Southern probe	iPCR
20	T15C16-T7	Southern probe	iPCR
	F10N5-Sp6	Southern probe	iPCR
	T24F13-Sp6	Southern probe	iPCR
	F28N8-Sp6	PCR diagnostic	BAC end sequence data (public)
	F5G10-T7	PCR diagnostic	BAC end sequence data (public)

Table 3. Oligonucleotides developed to identify the *VRN1* gene. The positive (+) strand oligos correspond to the forward, or mRNA, strand of DNA, and the negative (-) strand oligos correspond to the reverse, or coding, strand of DNA. The position indicated in the table refers to the nucleotide position in the *VRN1* genomic sequence (Annex I) of the 5' end of the oligo.

	Oligo	Strand	Position	Sequence (5' to 3')
10	S63	+	850	CAACGGTTAGCCCAAAC
	S64	-	866	GTTTGGGCTAACCGTTG
	V11	+	1193	GAGACCAGTTTTGTTTTCC
	S62	-	1229	GACAAATATAGGTGGAAAGG
	S66	+	1441	AAAGGGGAGTAGGTGGG
15	V7	+	1811	CTCTCTGGTCTTCTCTTC
	V10	-	1828	GAAGAGAAGACCAGAGAG
	V6	+	1907	TTTTCTCATCCACTATCC
	S51	-	1930	TTTCTTGGATAGTGGATGAG
	S65	-	2166	AAAACAGGGAAGAGTAAGAAG
20	S52	+	2270	CATTGGTTGTGTTTGGTGGG
	V5	+	2599	GGTCTCTATGTATTGTGC
	V4	-	2616	GCACAATACATAGAGACC
	V12	-	2846	AGATTGATTACACGACTCC
	V8	+	3125	CCCAGATAAGTTTGTGAG
25	V3	+	3391	ATTCCGCTCACAACCAC
	V15	-	3414	GTTTGAAGTGGTTGTGAG
	V14	+	3477	TACCCATCACCCTTCC
	S60	-	3474	CAGAAGAAGGAAAGATGACC
	S61	+	3927	GAAGAAAGAGAGAGAGCC
30	V13	+	3976	ACCCTTTCTTCAGAGTG
	V9	-	3942	CTCTCTCTCTTTCTTCTG
	V16	-	3993	CCACTCTGAAGAAAGGG
	S46	+	4096	CCTTCTGTTTCTGTTTCTC
	S45	-	4114	GAGAAACAGAAACAGAAGG
35	V2	-	4431	AAGATACTCCTACACGAC
	V17	+	4486	GTCTCGTTTTTTCTCTCGG
	S49	+	4870	CTACCACAGTTCCCACCTAC

Table 4 Sequences corresponding to ESTs for *VRN1* and *RTV1*, and sequences used for comparison to *VRN1* in Figures 8-12

	Name	Type	Description	Accession #
5	92M2	nucl	EST; <i>VRN1</i> transcript	T21005
	F2H7	nucl	EST; <i>VRN1</i> transcript	N95889
	105O22	nucl	EST; <i>RTV1</i> transcript	T22671
	151H18	nucl	EST; <i>RTV1</i> transcript	T76788
	247A13	nucl	EST; <i>RTV1</i> transcript	AA713228
10	89H14	nucl	EST; <i>RTV1</i> transcript	T20909
	89I23	nucl	EST; <i>RTV1</i> transcript	T20917
	VRN1	aa	Encoded by <i>VRN1</i> (putative)	N/A
	RTV1	aa	Encoded by <i>RTV1</i> (putative)	N/A
	3859591	aa	Putative <i>Arabidopsis</i> protein	AAC72857
15	CAA19759	aa	Putative <i>Arabidopsis</i> protein	CAA19759
	CAA19755	aa	Putative <i>Arabidopsis</i> protein	CAA19755
	CAA19754	aa	Putative <i>Arabidopsis</i> protein	CAA19754
	RAV1	aa	Putative <i>Arabidopsis</i> protein	BAA34250
	FUSCA3	aa	Putative <i>Arabidopsis</i> protein	AAC35246
20	ABI3	aa	Putative <i>Arabidopsis</i> protein	JQ1676
	ARF1	aa	Putative <i>Arabidopsis</i> protein	AAD39318
	IAA24	aa	Putative <i>Arabidopsis</i> protein	AAB92476
	c-MYC	aa	Putative <i>Carassius</i> <i>auratus</i> (goldfish) protein	P49709

Table 5 Comparison of the Nucleotide and Amino Acid Sequences of *RTV1* to *VRN1*

Sequence	Nucleotide s			Amino Acids			
	Id a	Length (bp)	Range ^b	Id a	Sim. c	Length (aa)	Range ^d
RTV1 complete	69	1026	269- 1291	67	74	341	1-341
RTV1 Region 1	49	283	272-550	42	44	93	2-94
RTV1 Region 2	71	429	551-981	71	82	144	95-238
RTV1 Region 3	84	314	982- 1291	95	99	103	239-341

a Identity (%)

b Numbered relative to *VRN1* transcript sequence (Figure 7)

c Similarity (%)

d Numbered relative to *VRN1* encoded amino acid sequence (Figure 7)

References

Abe, H., Yamaguchi-Shinozaki, K., Urao, T., Iwasaki, T., Hosokawa, D., and Shinozaki, K. (1997). Role of arabidopsis MYC and MYB homologs in drought- and abscisic acid- regulated gene expression. *Plant Cell* 9, 1859-68.

Abel, S., Oeller, P. W., and Theologis, A. (1994). Early auxin-induced genes encode short-lived nuclear proteins. *Proc Natl Acad Sci U S A* 91, 326-30.

Baker, S. S., Wilhelm, K. S., and Thomashow, M. F. (1994). The 5'-region of *Arabidopsis thaliana* cor15a has cis-acting elements that confer cold-, drought- and ABA-regulated gene expression. *Plant Mol Biol* 24, 701-13.

Barnes, J. A., and Gomes, A. V. (1995). PEST sequences in calmodulin-binding proteins. *Mol Cell Biochem* 149-150, 17-27.

Becker, D., Brettschneider, R., and Lorz, H. (1994). Fertile transgenic wheat from microprojectile bombardment of scutellar tissue. *Plant J* 5, 299-307.

Bell, C. J., and Ecker, J. R. (1994). Assignment of 30 Microsatellite Loci to the Linkage Map of Arabidopsis. *Genomics* 19, 137-144.

- 5 Bent, E., Johnson, S., and Bancroft, I. (1998). BAC representation of two low-copy regions of the genome of *Arabidopsis thaliana*. *Plant J* 13, 849-55.

10 ~~Camilleri, C., Lafleur, J., Macadre, C., Varoquaux, F.,~~
Parmentier, Y., Picard, G., Caboche, M., and Bouchez, D. (1998). A YAC contig map of *Arabidopsis thaliana* chromosome 3. *Plant J* 14, 633-42.

15 Chandler, J., Wilson, A., and Dean, C. (1996). *Arabidopsis* mutants showing an altered response to vernalization. *Plant Journal* 10, 637-644.

20 Chang, C., Bowman, J. L., DeJohn, A. W., Lander, E. S., and Meyerowitz, E. M. (1988). Restriction fragment length polymorphism linkage map for *Arabidopsis thaliana*. *Proc Natl Acad Sci U S A* 85, 6856-60.

25 Chevaillier, P. (1993). Pest sequences in nuclear proteins. *Int J Biochem* 25, 479-82.

Classon, M., Wennborg, A., Henriksson, M., and Klein, G. (1993). Analysis of c-Myc domains involved in stimulating SV40 replication. *Gene* 133, 153-61.

30 Cooper, K. F., Mallory, M. J., Smith, J. B., and Strich, R. (1997). Stress and developmental regulation of the yeast C-type cyclin Ume3p (Srb11p/Ssn8p). *Embo J* 16, 4665-75.

35 Frohman, M. A., Dush, M. K., and Martin, G. R. (1988). Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. *Proc Natl Acad Sci U S A* 85, 8998-9002.

40 Gilmour, S. J., and Thomashow, M. F. (1991). Cold-acclimation and cold-regulated gene-expression in ABA mutants of *Arabidopsis thaliana*. *Plant Molecular Biology* 17, 1233-1240.

Giraudat, J., Hauge, B. M., Valon, C., Smalle, J., Parcy, F., and Goodman, H. M. (1992). Isolation of the *Arabidopsis*

thaliana ABI3 (Absciscic acid-insensitive) gene by positional cloning. *The Plant Cell* 4, 1251-1261.

5 Goldsbrough, A. P., Albrecht, H., and Stratford, R. (1993). Salicylic acid-inducible binding of a tobacco nuclear protein to a 10 bp sequence which is highly conserved amongst stress-inducible genes. *Plant J* 3, 563-71.

10 ~~Gomes, A. V., and Barnes, J. A. (1997). Protein phosphatases are pest containing proteins. *Biochem Mol Biol Int* 41, 65-73.~~

15 Guilfoyle, T. J., Ulmasov, T., and Hagen, G. (1998). The ARF family of transcription factors and their role in plant hormone- responsive transcription. *Cell Mol Life Sci* 54, 619-27.

20 Hoekema, A., Hirsch, P. R., Hooykaas, P. J. J., and Schilperoort, R. A. (1983). A binary plant vector strategy based on separation of vir- and T-region of the *Agrobacterium tumefaciens* Ti-plasmid. *Nature* 303, 179-180.

Hooykaas, P. J. (1989). Transformation of plant cells via *Agrobacterium*. *Plant Mol Biol* 13, 327-36.

25 Jiang, C., Iu, B., and Singh, J. (1996). Requirement of a CCGAC cis-acting element for cold induction of the BN115 gene from winter *Brassica napus*. *Plant Mol Biol* 30, 679-84.

30 Kagaya, Y., Ohmiya, K., and Hattori, T. (1999). RAV1, a novel DNA-binding protein, binds to bipartite recognition sequence through two distinct DNA-binding domains uniquely found in higher plants. *Nucleic Acids Res* 27, 470-8.

35 Kerkhoff, E., and Bister, K. (1991). Myc protein structure: localization of DNA-binding and protein dimerization domains. *Oncogene* 6, 93-102.

40 Kim, J., Harter, K., and Theologis, A. (1997). Protein-protein interactions among the Aux/IAA proteins. *Proc Natl Acad Sci U S A* 94, 11786-91.

Koepp, D. M., Harper, J. W., and Elledge, S. J. (1999). How the cyclin became a cyclin: regulated proteolysis in the cell cycle. *Cell* 97, 431-4.

Laney, J. D., and Hochstrasser, M. (1999). Substrate targeting in the ubiquitin system. *Cell* 97, 427-30.

5 Liu, Y. G., Mitsukawa, N., Lister, C., Dean, C., and Whittier, R. F. (1996). Isolation and mapping of a new set of 129 RFLP markers in *Arabidopsis thaliana* using recombinant inbred lines. *Plant J* 10, 733-6.

10 Liu, Z. P., Galindo, R. L., and Wasserman, S. A. (1997). A role for CKII phosphorylation of the cactus PEST domain in dorsoventral patterning of the *Drosophila* embryo. *Genes Dev* 11, 3413-22.

15 Loake, G. J., Faktor, O., Lamb, C. J., and Dixon, R. A. (1992). Combination of H-box [CCTACC(N)7CT] and G-box (CACGTG) cis elements is necessary for feed-forward stimulation of a chalcone synthase promoter by the phenylpropanoid-pathway intermediate p-coumaric acid. *Proc Natl Acad Sci U S A* 89, 9230-4.

20 Luerksen, H., Kirik, V., Herrmann, P., and Misera, S. (1998). FUSCA3 encodes a protein with a conserved VP1/AB13-like B3 domain which is of functional importance for the regulation of seed maturation in *Arabidopsis thaliana*. *Plant J* 15, 755-64.

25 Macknight, R., Bancroft, I., Page, T., Lister, C., Schmidt, R., Love, K., Westphal, L., Murphy, G., Sherson, S., Cobbett, C., and Dean, C. (1997). *FCA*, a gene controlling flowering time in *Arabidopsis*, encodes a protein containing RNA-binding domains. *Cell* 89, 737-745.

30 Mannervik, M., Nibu, Y., Zhang, H., and Levine, M. (1999). Transcriptional coregulators in development. *Science* 284, 606-9.

35 Marchal, C., Hagenauer-Tsapis, R., and Urban-Grimal, D. (1998). A PEST-like sequence mediates phosphorylation and efficient ubiquitination of yeast uracil permease. *Mol Cell Biol* 18, 314-21.

40 Maule, J. (1997). Physical mapping by pulsed-field gel electrophoresis. *Methods Mol Biol* 68, 93-121.

McCarty, D. R., Hattori, T., Carson, C. B., Vasil, V., Lazar,

M., and Vasil, I. K. (1991). The Viviparous-1 developmental gene of maize encodes a novel transcriptional activator. *Cell* 66, 895-905.

- 5 McKinsey, T. A., Chu, Z. L., and Ballard, D. W. (1997). Phosphorylation of the PEST domain of IkappaBbeta regulates the function of NF-kappaB/IkappaBbeta complexes. *J Biol Chem* 272, 22377-80.
- 10 Mhiri, C., Morel, J. B., Vernhettes, S., Casacuberta, J. M., Lucas, H., and Grandbastien, M. A. (1997). The promoter of the tobacco Tnt1 retrotransposon is induced by wounding and by abiotic stress. *Plant Mol Biol* 33, 257-66.
- 15 Mozo, T., Fischer, S., Shizuya, H., and Altmann, T. (1998). Construction and characterization of the IGF Arabidopsis BAC library. *Mol Gen Genet* 258, 562-70.
- 20 Nordin, K., Vahala, T., and Palva, E. T. (1993). Differential expression of two related, low-temperature-induced genes in *Arabidopsis thaliana* (L.) Heynh. *Plant Mol Biol* 21, 641-53.
- 25 Rechsteiner, M., and Rogers, S. W. (1996). PEST sequences and regulation by proteolysis. *Trends Biochem Sci* 21, 267-71.
- Rogers, S., Wells, R., and Rechsteiner, M. (1986). Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. *Science* 234, 364-8.
- 30 Schmidt, E. V. (1999). The role of c-myc in cellular growth control. *Oncogene* 18, 2988-96.
- Schmidt, R., and Dean, C. (1995). Hybridization analysis of YAC clones. *Methods in Mol. & Cell. Biol.* 5, 309-318.
- 35 Steger, D. J., Utley, R. T., Grant, P. A., John, S., Eberharther, A., Cote, J., Owen-Hughes, T., Ikeda, K., and Workman, J. L. (1998). Regulation of transcription by multisubunit complexes that alter nucleosome structure. *Cold Spring Harb Symp Quant Biol* 63, 483-91.
- 40 Stockinger, E. J., Gilmour, S. J., and Thomashow, M. F. (1997). *Arabidopsis thaliana* CBF1 encodes an AP2 domain-containing transcriptional activator that binds to the C-repeat/DRE, a

cis-acting DNA regulatory element that stimulates transcription in response to low temperature and water deficit. Proc Natl Acad Sci U S A 94, 1035-40.

- 5 Stone, J., de Lange, T., Ramsay, G., Jakobovits, E., Bishop, J. M., Varmus, H., and Lee, W. (1987). Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol 7, 1697-709.
-
- 10 Suzuki, M., Kao, C. Y., and McCarty, D. R. (1997). The conserved B3 domain of VIVIPAROUS1 has a cooperative DNA binding activity. Plant Cell 9, 799-807.
 - 15 Thomashow, M. F. (1994). *Arabidopsis thaliana* as a model for studying mechanisms of plant cold tolerance. In *Arabidopsis* (New York: Cold Spring Harbor Laboratory Press), pp. 807-834.
 - 20 Torchia, J., Glass, C., and Rosenfeld, M. G. (1998). Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 10, 373-83.
 - 25 Ulmasov, T., Hagen, G., and Guilfoyle, T. J. (1997). ARF1, a transcription factor that binds to auxin response elements. Science 276, 1865-8.
 - 30 Urao, T., Yamaguchi-Shinozaki, K., Urao, S., and Shinozaki, K. (1993). An *Arabidopsis* myb homolog is induced by dehydration stress and its gene product binds to the conserved MYB recognition sequence. Plant Cell 5, 1529-39.
 - 35 Vierstra, R. D. (1996). Proteolysis in plants: mechanisms and functions. Plant Mol Biol 32, 275-302.
 - Yaglom, J. A., Goldberg, A. L., Finley, D., and Sherman, M. Y. (1996). The molecular chaperone Ydj1 is required for the p34CDC28-dependent phosphorylation of the cyclin Cln3 that signals its degradation. Mol Cell Biol 16, 3679-84.

Annex I - Ler VRN1 genomic (contig 29 [1501-6500])

	1	10	20	30	40
	TTTAA	AATT	TCGA	ATTGGG	ATTTAAGAAAAATTCTCATCAA
5	ATATTT	TATCAT	TAGTGT	ATATATAT	CAGTGTTTTACATTT
	GTTAAT	CCTAA	ATAATA	AAACCG	ATCTGAAAAGTTGATAAA
	TGCGTT	GTCAA	AAAGACA	AAATATA	CATCCAAACAAATCAC
	GTGATT	GCCTT	CAACTT	GGCCAC	gGGTTCAAAGATTTAACA
	AATCTT	CTAAA	ACCAACT	TAAACCC	ACGAATACACAAGC
10	ACAGAG	TGGTGG	TAAACAT	ACAAGTT	AATGAGTTATTCAA
	ATGAGAT	TTTTCA	ATATCAT	TCTTCT	TTCAGCCCGTCACAAG
	AAGCCA	AGATTA	AGCCATT	AGAGGA	AGTTTATAAACCGAC
	AAAACCT	GTCTTA	GATACAA	AGAATA	CTAGCTAATGTGTTT
	CAACAA	ACTTCA	AATTGAC	GATACGT	TACATTCATATTAA
15	TCACTT	CAGAGC	TTGATT	ATTCAA	ATTATTTTTTCTACTG
	TGATAC	ATATAT	ACACAT	GTTTTG	CTTTTCTATGATTC
	TATCTA	CATTTTC	ATACCG	TTGAATA	ATTTATGTATGAAT
	TACGAT	GCAATTT	CCCTTCA	TATGCT	TGAATAAAATGCTT
	TTGGAC	ATGCAT	GCGATAT	TGGATCT	ACTTTTGGATTCTA
20	TTTTTA	AAAAAT	CAGCGA	GTTTGTT	GCTTTGTAAATTTTAA
	TTAGGC	ATCAAG	AATTTCT	AAAATGC	ACGCGAACTGGTGA
	AAAGAG	GAATGTT	TACGTTT	TACCCCT	TTATTTTCTTACAG
	CTCATA	AAGGATA	CTGTCAG	AAGACAG	AACCAAGGCTCTCT
	GACTATA	AAATTG	GAAATCC	ATTTAA	ACATAATGTTATGACC
25	AATGAT	GGCCA	ACGGTT	AGCCCAA	CTAATTA
	CAAGTT	CCAATAT	TCTAAG	GAGAAAT	AATAGTATACTAA
	ACATAC	ATTAG	AGAGGT	TAAACT	TCTTTTGGATT
	GTGTAT	GCATAG	GCTATTT	TATTCT	TAAGTATAACTATT
	CTGTAG	CTAGAT	TTTATA	CAAGAA	TACATAAACTTTAT
30	CATGTG	AGGTAG	CCATGA	ATATAC	GTACATGTTGCAAT
	ATTATA	CATGTT	GTATTT	TGGATT	TCTCTATACATGTT
	ACTTGT	CATTCT	CTAAGT	ATATAC	ATACTTAATACTGT
	GGGCAT	GAGTTT	ATGATA	AAGACT	TTTTCTTTTGGAG
	TTTTGT	TTTTC	CTTTCC	ACCTAT	ATTTGTCTATAGG
35	CTCa	gACGGT	ACACTA	GTTTACA	AGTGTTTTTATAT
	GTTCTA	AAATTA	AGATTT	TCCGGA	ACGGTATGATCTG
	TTTGCA	ATAAGG	ACGTAT	ATATATA	TTTGTGTTGT
	TATAAG	GCAATA	ATATAT	TTTCTG	AGATATTGCGTG
	TTAC	AAAAA	AGAAAT	ATTTGT	TAAAGAAAAAAGAT
	GGTC	GAA	AAAGGG	GAGTAG	GTGGGGCGGTCGG
40	CTTTT	GATTAG	TGTTA	ATAAAA	AGAAACCAACGAG
	TGACCT	ACCGAT	TCGACT	CAA	CGAGTCTACCGAG
	CTAAC	ACAGAT	TCAACT	CGCTCG	AGCTTCGTTTAT
	GACAAG	TGGTTT	TTTTTTTT	TTTTTTT	TAATTTTTT
	TAAT	TTTTT	CATCTT	CTTGGG	TTTGGTTGGGTCA
	CTTCAG	GT	CAGGT		
45	CAGGT	GTGTAA	AAAAA	AGAAAG	AAAAGAGAGATTG

TGTTGTAACCCCTTTGACTAAAATCTAATGAACTTTTTTA
ACACAACAAAACCTTCCTTCAGATCTGAAAGGGTTCTTCTTC
TCTCTTAGTCTCTTTGTCCTTTTATTCTCCGTCGTCGTTT
CATGATCTGACTCTCTGGTCTTCTCTTCTTCTTCTTCTTC
5 TTCTATTTTTTCTTACTTCGTCACTGTTGTGTCTGAACAT
GCCACGCCCTTTCTTCCATAAGTTGATTTTCTCATCCACT
ATCCAAGAAAAACGTCTGGTAACTTACTCTCTCTCTCTCT
CTCTCTCTCTGTTCTCCTTCTCCTCATCTTTCAAAGTTTT
GATTTTGTGCGAAATTGAGGGTTTTCAAGGTTTGGAATCT
10 GGTGAACGAGTTTGTAAGATTATGCCTTGTGACACTCTTG
CTTGATTTCTTACAATTCACCTTGATTGATTCTTTGTAAG
AATCGAGTCAAGGTTGTGCTTTTATCTTCTTACTCTTCCC
TGTTTTGGGTAATGAAAAGAAGTTCCATTTTTGAACTTTG
TGTTGTCTTATTGGTCAAATGAGAATTTGTGGGTTTCCAA
15 TGGAAGTCTGCAAGACAGTTTCTTTTGGTCATTGGTTGTG
TTTGGTGGGAAATTGGGTATTTGATGGTATATCTGTACTC
TGACAGCATATTGTGTGTAGTTTGGGAATTTTTTTTTTTT
TTTTGAGTGATTTGACTTTTGGAGGACGATTTGATTCTGT
CAGATTGATCAAATTTCTTCTGAGGAGAAAAAGTTGAGAT
20 CTGTTTATGGTTTCTCTATTATAAATGTCTGTTTTGTTTA
CTCTATTTTGACTGTTTTCTCTGTTTGACTTAGGAATGTC
TGAGATCTTAGACTCCTTATTGAGTATTGTGtGGCTTGTG
AGTGAATCCCTAAAACTGAGTAGTTGACTTGTTTTGAAGG
TCTCTATGTATTGTGCTTATGTTTTAAAGTTGTCTACTTT
25 ATTTGATACAGTGATTAGTCATCACTTGTACAGATTCCCC
CAAGAGCATTGTTTTGAACAAATCCAAATTTGCTTAGCTC
TCCATTTGGCATTTAAGTGACTAGATTTTCTCTGGAATAA
TGATTTTCGATTAACACAGGCATTTATGTGGAACCAAGTTT
GCAAATTATTAATGTGATAAGATCATAGGAGTCGTGTAAT
30 CAATCTATTACAGAGATAAATGTACCATTTTACATGTGTAC
TAATGGACTGTGTCTCCTTGTTGATGCCTTCTCTAAACTG
AAATATGGCCTTTTGGTTTGTGTTTTTAAATTAGGTAAAG
CCGTCGTTTCTTCAGCTACTGTGTTTATTGGATGTTTTTG
CTGAAAAATGTCTGTTTCGATTTGATGTTCTCGCAATATT
35 CTGTGCTGTTCTTATAGATATTGTGGACATTTATATCATT
ATATGCTTCTTTATATCTCATACCGGCATGCTTGTGCAGA
GGGTCCCAGATAAGTTTGTGAGTAAATTCAAGGATGAGCT
TTCGGTTGCTGTTGCACTCACAGTACCTGATGGTCATGTT
TGRCGTGTAGGACTAAGGAAAGCTGACAACAAAATTTGGT
40 TTCAAGATGGTTGGCAAGAGTTTGTGACCGTTACTCCAT
TCGCATTGGTTATCTTTTGATTTTATGATATGAAGGAAAC
TCTGCCTTCAGCGTCTACATTTTCAATTTATCCCACCTCTG
AGATCAATTACCATTCCACCGGTCTCATGGATTCCGCTCA
CAACCACTTCAAACGCGCCCGTTTGTGTTGAAGACCTTGAA
45 GATGAAGATGCCGAGGTCATCTTTCCTTCTTCTGTGTACC

CATCACCCTTCCTGAGTCTACAGTACCAGCCAACAAAGG
GTATGCTAGTTCAGCCATCCAAACCTTGTTCACTGGACCA
GTTAAAGGTGATATTTATAACCAACTGATTCCCTTTATCT
ATCGCTGATTACGCGTCTTATCATTCTTTTGAGGTTGATG
5 CTTGATATTTTCCTTATCTCCAGCTGAAGAGCCAACGCCA
ACCCCAAAAATACCTAAAAAGAGAGGGAGGAAGAAGaAAA
ATGCTGATCCTGGTAAGCACTTTTCCTCTTTGAAATGCTT
CAGACTCGTTTTTCAGAGGATTCACAGATTCTTCCTCATGA
TACATATATCCTTTTGATATTGTCCTTACAGAGGAAATAA
10 ACTCATCAGCTCCGCGAGATGATGATCCAGAGAACCGTTC
AAAGTTCTACGAGAGTGCTTCTGCGAGAAAGAGAACCGTG
ACTGCAGAAGAAAGAGAGAGAGCCATCAATGCAGCCAAAA
CGTTCGAACCAACAAACCTTTCTTCAGAGTGGTTCTGCG
ACCATCCTATCTATACAGAGGTTGCATCATGGTAATAAAA
15 AAACATCTTAGGAAGACTTAATCTTATCGGTGTCTTCACT
GATCTCTAAAAGAAGCCTTCTGTTTCTGTTTCTCTCAACA
GTATCTTCCTTCTGGGTTTGCTGAGAAGTACCTAAGTGGG
ATCTCCGGGTTTCATCAAAGTCCAGCTTGCGGAGAAACAAT
GGCCTGTTTCGATGTCTCTACAAAGCCGGGAGAGCCAAATT
20 CAGTCAAGGATGGTACGAATTCCTCTAGAGAACAACTTA
GGAGAAGGAGACGTCTGTGTGTTTGAGCTGCTCAGAACCA
GAGATTTTCGTTTTGAAAGTGACAGCCTTTCGAGTCAACGA
GTACGTCTGAACAAAGCATTATGGTGTGATCATTCTGGAT
TTGCAAGTACAATGTTCGTGTAGGAGTATCTTAATTTAAAA
25 ACAACTAAAAAACTCTCTTCTGGTCTGTGTCATTATTGCG
TCAGTGTCTCGTTTTTTCTCTCGGGTTTACTTTGTGTTAT
CGATGTGGATAAGTTGTTTTTACCTCATTATATATAACCT
CTTGAGTGGAACCTCAAATTGTTTGAGTAGAACAAACAAAG
TTAGGGTTTAAGAAGAAGTCTGTAAATACCTAATCTCCAT
30 CAAATTTGAGTAGAAAGACAACTGTTCTGGTGGAATACA
AGGAGGGAACTTGAGATAACAACTTAAGAATAGCCTTCA
AGCCAACGTCTAGAATTTGATGAAGTTGTTGTTTGATCAC
CTCTGAGATAATTGGAAACCTCTTCATGCAGTTTGCTTG
AGGATACTGGTGAAAATGGGAGTATTGAAGGAAAATGCAT
35 ATATAAGATTGTAGGTGGGAACTGTGGTAGCAGACACAAC
ACTTGTTCTCTAGACATATACTGTACCAGACATGTTTTGA
TCATAAACTTAAAAAAAAGAAAACCGTGTGTAAATCAAG
CAAGGAACAACCTACAATATTACAATCTTATTGAGATATCA

Figure 1

Fig.1A --- Long Days




Fig. 1B --- Short Days






Figure 2:






Figure 3






Figure 4.






Figure 5







Figure 6





	TCTTGGGTTTGGTTGGGTCACTCTTCAGGTCAGGTGTTGTGTA	43
AAGAAAGAAAGAAAAGAGAGATTGTTGTGTTGTAACCCCTTTGACTAAAATCTAATGAACCTTTTTTAACACAACA		118
AAACTCCTTCAGATCTGAAAGGGTCTCTTCTCTCTCTTAGTCTCTTTGTCCCTTTATTCTCCGTCGTCGTTTCAT		193
GATCTGACTCTCTGGTCTTCTCTTCTTCTTCTTCTTCTATTTTTTCTTACTTCGTCACCTGTTGTGTCTGAAC		268
ATGCCACGCCCTTTCTTCCATAAGTTGATTTTCTCATCCACTATCCAAGAAAAACGTCTGAGGGTCCCAGATAAG	▼	343
<u>M P R P F F H K L I F S S T I Q E K R L R V P D K</u>		25
TTTGTGAGTAAATTCAAGGATGAGCTTTCGGTTGCTGTTGCACTCACAGTACCTGATGGTCATGTTTGGCGTGTA	TGA in <i>vrn1-1</i>	418
<u>F V S K F K D E L S V A V A L T V P D G H V (W) R V</u>		50
GGACTAAGGAAAGCTGACAACAAAATTGGTTTCAAGATGGTTGGCAAGAGTTTGGTTGACCGTTACTCCATTCCGC		493
<u>G L R K A D N K I W F Q D G W Q E F V D R Y S I R</u>		75
ATTGGTTATCTTTTGATTTTTAGATATGAAGGAACTCTGCCTTCAGCGTCTACATTTTCAATTTATCCCACTCT		568
<u>I G Y L L I F R Y E G N S A F S V Y I F N L S H S</u>		100
GAGATCAATTACCATTCCACCGGTCTCATGGATTCCGCTCACAAACCACTTCAAACGCGCCCGTTTGGTTTGAAGAC		643
<u>E I N Y H S T G L M D S A H N H F K R A R L F E D</u>		125
CTTGAAGATGAAGATGCCGAGGTATCTTTCTTCTTCTGTGTACCCATCACCCTTCTGAGTCTACAGTACCA		718
<u>L E D E D A E V I F P S S V Y P S P L P E S T V P</u>		150
GCCAACAAGGGTATGCTAGTTCAGCCATCCAAACCTTGTTCCTGACGAGTTAAAGCTGAAGACCAACGCCA	▼	793
<u>A N K G Y A S S A I Q T L F T G P V K A E E P T P</u>		175
ACCCCAAAATACCTAAAAAGAGAGGGAGGAAGAAGAAAAATGCTGATCCTGAGGAAATAAACTCATCAGTCCG	G-A in <i>vrn1-2</i>	868
<u>T P K I</u> <u>P K K R G R K K K (N)</u> A D P E E I N S S A P	▼	200
CGAGATGATGATCCAGAGAACCCTTCAAAGTTCTACGAGAGTGCTTCTGCGAGAAAGAGAACCCTGACTGCAGAA		943
<u>R D D D P E N R S K F Y E S A S A R K R T V T A E</u>		225
GAAAGAGAGAGAGCCATCAATGCAGCCAAAACGTTTGAACCAACAAACCTTTCTTTCAGAGTGGTTCTGCGACCA		1018
<u>E R E R A I N A A K T F E P T N P F F R V V L R P</u>		250
TCCTATCTATACAGAGGTTGCATCATGTATCTTCCTTCTGGGTTTGTCTGAGAAGTACCTAAGTGGGATCTCCGGG	▼	1093
<u>S Y L Y R G C I M Y L P S G F A E K Y L S G I S G</u>		275
TTTCATCAAAGTCCAGCTTTCGCGAGAAAACATGGCCTGTTTCATGTCTCTACAAAGCCGGGAGAGCCAAATTCAGT		1168
<u>F I K V Q L A E K Q W P V R C L Y K A G R A K F S</u>		300
CAAGGATGGTACGAATTCCTCTAGAGAACAACCTTAGGAGAAGGAGACGTCTGTGTGTTTGTAGCTGCTCAGAACC		1243
<u>Q G W Y E F T L E N N L G E G D V C V F E L L R T</u>		325
AGAGATTTTCGTTTTGAAAGTGACAGCCTTTTCGAGTCAACGAGTACGTCTGAACAAAGCATTATGGTGTGATCATT		1318
<u>R D F V L K V T A F R V N E Y V</u>		341
CTGGATTTGCAAGTACAATGTCGTGTAGGAGTATCTTAATTTAAAAACAACATAAAAACTCTCTTCTGGTCTGTG		1393
TCATTATTTCGTCAGTGCTCGTTTTTCTCTCGGGTTTACTTTGTGTTATCGATGTGGATAAGTTGTTTTTACC		1468
TCATTATATATAACCTCTTTGAGTGGAA		1495


7/9



		*	20	*	40	*	60		
VRN1	MPRPFFHK--LIFSS	IQEKRLRVPDKFVSKFKDEL	SVAVALTVPDGHVWRV	GLRKADN	57				
RTV1	MPRSFFHMFNSLFLSST	QAS-----	-----	GLRKANN	27				
<hr/>									
		*	80	*	100	*	120		
VRN1	KIWFODGWOFVD	DRYSIRIGYLLI	FRYEENSASF	SVYIFN--IS	HSEIN	YST--GLM--D	111		
RTV1	KIWFODGWOFVN	RRESIRIG---	FRYKIV----	TVIYIFQFYEP	HSEINEHS	SEALMQMD	79		
<hr/>									
		*	140	*	160	*	180		
VRN1	SAHNHF-KRARLFEDLE	DEDAE	VIEFPSS	VYPSP	LPESTVPANKGYA-SSAIQL	LTGPVK	169		
RTV1	SAQNQFNKRARLFEDLE	ELKDAK	VIVPSN-----	PESTE	PVNKGYGSTAIQSFE	KES-K	132		
<hr/>									
		*	200	*	220	*	240		
VRN1	AEEPTPTPKTKKKRGRKKKNAD	PEEI	NSSAPRD	DDPENRSKFYESASARKRTVTAEERER	229				
RTV1	AEE---TPKVTKKKRGRKKKNPN	PEEV	NSSTPGGDDS	ENRSKFYESASARKRTVTAEERER	189				
<hr/>									
		*	260	*	280	*	300		
VRN1	AINAAKTPEPTNP	FRVVLRPSYL	YRGCI	MYLP	SGFAEKYLSGISGFIKVLNEKOWPVR	289			
RTV1	AINAAKTPEPTNP	FRVVLRPSYL	YRGCI	MYLP	SGFAEKYLSGISGFIKVLNEKOWPVR	249			
<hr/>									
		*	320	*	340	*			
VRN1	CLYKAGRAKFSOGWYEFTLENNI	GEGDV	CVFELL	RTRDFVL	KVTAFRVNEYV	341			
RTV1	CLYKAGRAKFSOGWYEFTLENNI	GEGDV	CVFELL	RTRDFVL	EVTAFRVNEYV	301			



Figure 9



Probe: VRN1 cDNA V2V6

PCT/GB001 03525

newborn Elus

13/9/00